



LUMOS DIAGNOSTICS HOLDINGS LIMITED
ACN 630 476 970

Notice of Annual General Meeting

Explanatory Statement and Proxy Form

Date of Meeting:
Friday, 13 November 2026

Time of Meeting:
9:00am (AEDT)

Location of Meeting: Zoom Webinar
Registration Link: https://vistra.zoom.us/webinar/register/WN_Q_B5tsN-TH-VRNHi40k4jQ

The Meeting will be held virtually via a webinar conferencing facility. If you are a Shareholder who wishes to attend and participate in the virtual Meeting, please register in advance as per the instructions outlined in this Notice of Meeting. Shareholders are strongly encouraged to lodge their completed proxy forms in accordance with the instructions in this Notice of Meeting.

The Notice of Meeting has been given to those entitled to receive it by use of one or more technologies. The Notice of Meeting is also available on the Australian Securities Exchange Market Announcements Platform and on the Company's website www.lumosdiagnostics.com.

This Notice of Annual General Meeting and Explanatory Statement should be read in its entirety. If Shareholders are in doubt as to how they should vote, they should seek advice from their accountant, solicitor or other professional advisor without delay.

LUMOS DIAGNOSTICS HOLDINGS LIMITED

ACN 630 476 970

Registered office: Suite 2, Level 11, 385 Bourke Street, Melbourne VIC 3000

NOTICE OF ANNUAL GENERAL MEETING

Notice is hereby given that the Annual General Meeting of Shareholders of Lumos Diagnostics Holdings Limited (the “Company” or “LDX”) will be held via Zoom Webinar at 9:00am (AEDT) on Friday, 13 November 2026 (“Annual General Meeting”, “AGM” or “Meeting”).

The Directors have determined pursuant to Regulation 7.11.37 of the *Corporations Regulations 2001* (Cth) that the persons eligible to vote at the Meeting are those who are registered Shareholders at 7:00pm (AEDT) on Wednesday, 11 November 2026.

Shareholders are encouraged to submit their proxies as early as possible, and in any event, prior to the cut-off for proxy voting as set out in the Notice. To lodge your proxy, please follow the directions on your personalised proxy form.

Shareholders attending the AGM virtually will be able to ask questions and the Company has made provision for Shareholders who register their attendance before the start of the Meeting to also cast their votes on the proposed resolutions at the AGM.

The virtual Meeting can be attended by registering through the link below:

When: Friday, 13 November 2026 at 9:00am (AEDT)

Topic: LDX: 2026 Annual General Meeting

Register in advance for this webinar:

https://vistra.zoom.us/webinar/register/WN_Q_B5tsN-TH-VRNHi40k4jQ

After registering, you will receive a confirmation email containing information about joining the Meeting. As noted previously, the Company strongly recommends its Shareholders to lodge a directed proxy as soon as possible in advance of the Meeting even if they are planning to attend the Meeting online. The Company will conduct a poll on each resolution presented at the Meeting. The Company will accept questions during the Meeting either by submitting a question through the Q&A box located on screen or by raising the hand function also located on screen at which point the Company will allow your question verbally.

The Company is happy to accept and answer questions submitted prior to the Meeting by email to cosec@lumosdiagnostics.com. The Company will address relevant questions during the course of the Meeting or by written response after the Meeting (subject to the discretion of the Company not to respond to unreasonable and/or offensive questions).

Any Shareholders who wish to attend the AGM online should therefore monitor the Company’s website and its ASX announcements for any updates about the AGM. If it becomes necessary or appropriate to make alternative arrangements for the holding or conducting of the Meeting, the Company will make further information available through the ASX website at asx.com.au (ASX: LDX) and on its website at <https://lumosdiagnostics.com/invest>.

AGENDA

The Explanatory Statement and Proxy Form which accompany and form part of this Notice, including defined terms and describe in more detail the matters to be considered. Please consider this Notice, the Explanatory Statement and the Proxy Form in their entirety.

Defined terms used in this Notice have the meanings given to them in the Glossary at the end of this Notice.

ORDINARY BUSINESS

Receipt and consideration of Financial Statements and Reports

To receive and consider the Annual Report of the Company for the financial year ended 30 June 2026, which includes the Financial Report, the Directors' Report, and the Auditor's Report.

Note: Except for as set out in Resolution 1, there is no requirement for Shareholders to approve these reports. Accordingly, no resolution will be put to Shareholders on this item of business.

Resolution 1: Adoption of Remuneration Report

To consider and, if thought fit, to pass the following resolution as an **ordinary resolution**:

"That for the purpose of section 250R(2) of the Corporations Act and for all other purposes, the Remuneration Report (included in the Directors' Report) for the financial year ended 30 June 2026 be adopted."

Note: In accordance with section 250R(3) of the Corporations Act, the vote on Resolution 1 is advisory only and does not bind the Directors or the Company. The Directors will consider the outcome of the vote and comments made by Shareholders on the Remuneration Report at the Meeting when reviewing the Company's remuneration policies.

A voting prohibition applies to this Resolution as outlined in Note 6.

Resolution 2: Election of Aizaz Syed as a Director of the Company

To consider and, if thought fit, to pass the following resolution as an **ordinary resolution**:

"That, for the purposes of clause 46(b) of the Constitution and Listing Rule 14.4 and for all other purposes, Aizaz Syed, having been appointed to the Board of Directors since the previous annual general meeting, and who vacates the office in accordance with the Constitution and Listing Rule 14.4, and who, being eligible, offers himself for election, be elected as a Director of the Company."

There are no voting exclusions or prohibitions on this Resolution.

Resolution 3: Re-election of Catherine Robson as a Director of the Company

To consider and, if thought fit, pass the following resolution as an **ordinary resolution**:

"That, for the purposes of Clause 47(a) of the Constitution, Listing Rule 14.4, and for all other purposes, Catherine Robson, who retires by rotation in accordance with the Constitution of the Company, and who, being eligible, offers herself for re-election, be re-elected as a Director of the Company."

There are no voting exclusions or prohibitions on this Resolution.

Resolution 4: Approval to issue Free Attaching Options under Share Purchase Plan to Mr Samuel Lanyon

To consider and, if thought fit, pass the following resolution as an **ordinary resolution**:

"That, for the purposes of Listing Rule 10.11 and for all other purposes, approval be given to issue and allot a maximum of 66,666 free attaching options, and the issue of any shares in the Company pursuant to the exercise of such free attaching options in the Company to Mr Samuel Lanyon (Director of the Company) (or his nominee) as part of the Share Purchase Plan as announced on 27 March 2026 on the terms and conditions set out in the Explanatory Statement which accompanies and forms part of this Notice."

A voting exclusion and prohibition applies to this Resolution as outlined in Note 6.

Resolution 5: Approval to issue Free Attaching Options under Share Purchase Plan to Ms Catherine Robson

To consider and, if thought fit, pass the following resolution as an **ordinary resolution**:

"That, for the purposes of Listing Rule 10.11 and for all other purposes, approval be given to issue and allot a maximum of 66,666 free attaching options, and the issue of any shares in the Company pursuant to the exercise of such free attaching options in the Company to Ms Catherine Robson (Director of the Company) (or her nominee) as part of the Share Purchase Plan as announced on 27 March 2026 on the terms and conditions set out in the Explanatory Statement which accompanies and forms part of this Notice."

A voting exclusion and prohibition applies to this Resolution as outlined in Note 6.

Resolution 6: Approval to issue 17,849,593 performance rights to Mr Douglas Ward (or his nominee) as a Long Term Incentive

To consider and, if thought fit, pass the following resolution as an **ordinary resolution**:

"That the grant of 17,849,593 performance rights (being a right to acquire up to 17,849,593 fully paid ordinary shares in the Company as a Long Term Incentive, subject to satisfaction of relevant vesting conditions) and the issue of any fully paid ordinary shares in the Company pursuant to the conversion of such performance rights, to Mr Douglas Ward, Managing Director and Chief Executive Officer of the Company, under the Company's Long Term Incentive Plan and on the terms described in the Explanatory Statement, be approved under and for the purpose of Listing Rule 10.14, sections 200B and 200E of the Corporations Act and for all other purposes."

A voting exclusion and prohibition applies to this Resolution as outlined in Note 6.

Resolution 7: Ratification of the issue of 88,888,876 Placement Shares

To consider and, if thought fit, pass the following resolution as an **ordinary resolution**:

"That, for the purposes of ASX Listing Rule 7.4 and for all other purposes, Shareholders ratify the issue on 9 April 2026 of 88,888,876 fully paid ordinary shares in the Company to the Placement Participants as described in the Explanatory Statement."

A voting exclusion applies to this Resolution as outlined in Note 6.

Resolution 8: Ratification of the issue of Placement and Share Purchase Plan Free Attaching Options

To consider and, if thought fit, pass the following resolution as an **ordinary resolution**:

"That, for the purposes of ASX Listing Rule 7.4 and for all other purposes, Shareholders ratify the issue on 1 May 2026 of 44,899,966 free attaching options with an exercise price of \$0.34 (34 cents) and expiring on 31 December 2027 in the Company to participants under the Placement and Share Purchase Plan as announced on 27 March 2026 as described in the Explanatory Statement."

A voting exclusion applies to this Resolution as outlined in Note 6.

Resolution 9: Renewal of the Company's Long-Term Incentive Plan

To consider and, if thought fit, to pass the following resolution as an **ordinary resolution**:

"That, under and for the purposes of ASX Listing Rule 7.2 Exception 13(b), and for all other purposes, approval is given for the Company to issue Equity Securities under the Company's Long-Term Incentive Plan as an exception to Listing Rule 7.1 on the terms and conditions as set out or described in the Explanatory Statement which accompanies and forms part of this Notice of Meeting."

A voting exclusion and prohibition applies to this Resolution as outlined in Note 6.

SPECIAL BUSINESS

Resolution 10: Approval of 10% Placement Facility

To consider and, if thought fit, pass the following resolution as a **special resolution**:

“That, pursuant to and in accordance with Listing Rule 7.1A and for all other purposes, Shareholders approve the issue of Equity Securities up to 10% of the fully paid ordinary issued capital of the Company (at the time of the issue) calculated in accordance with the formula prescribed in Listing Rule 7.1A.2 and on the terms and conditions in the Explanatory Statement.”

A voting exclusion applies to this Resolution as outlined in Note 6.

By the order of the Board

A handwritten signature in black ink, appearing to read 'Tracy Weimar', with a stylized flourish at the end.

Tracy Weimar
Company Secretary
Dated: 12 October 2026

Notes

1. **Entire Notice:** The details of the resolutions contained in the Explanatory Notes accompanying this Notice of Meeting should be read together with, and form part of, this Notice of Meeting.
2. **Record Date:** The Company has determined that for the purposes of the Annual General Meeting, Shares will be taken to be held by the persons who are registered as holding the Shares at 7:00pm (AEDT) on the date 48 hours before the date of the Annual General Meeting. Only those persons will be entitled to vote at the Annual General Meeting and transfers registered after that time will be disregarded in determining entitlements to attend and vote at the Annual General Meeting.
3. **Proxies**
 - a. Votes at the Annual General Meeting may be given personally or by proxy, attorney or representative.
 - b. Each Shareholder has a right to appoint one or two proxies.
 - c. A proxy need not be a Shareholder of the Company.
 - d. Where a Shareholder is entitled to cast two or more votes, the Shareholder may appoint two proxies and may specify the proportion or number of votes each proxy is appointed to exercise.
 - e. If a Shareholder appoints two proxies, and the appointment does not specify the proportion or number of the Shareholder's votes, each proxy may exercise half of the votes. If a Shareholder appoints two proxies, neither proxy may vote on a show of hands.
 - f. A proxy must be signed by the Shareholder or their attorney who has not received any notice of revocation of the authority. Proxies given by corporations must be signed in accordance with corporation's constitution and Corporations Act.
 - g. To be effective, Proxy Forms must be received by the Company's share registry (Computershare Investor Services Pty Ltd) no later than 48 hours before the commencement of the Meeting, this is no later than 9:00am (AEDT) on Wednesday, 11 November 2026. Any proxy received after that time will not be valid for the scheduled Meeting.
4. **Corporate Representative**

Any corporate Shareholder who has appointed a person to act as its corporate representative at the Meeting should provide that person with a certificate or letter executed in accordance with the Corporations Act authorising them to act as that company's representative. The authority may be sent to the Company and/or registry in advance of the Meeting or upon registering as a corporate representative.
5. **How the Chair will vote Undirected Proxies**

Subject to the restrictions set out in Note 6 below, the Chair of the Meeting will vote undirected proxies in favour of all proposed resolutions the subject of this Meeting.
6. **Voting Prohibitions and Voting Exclusions**

Resolution 1

In accordance with sections 250R(4) and 250BD(1) of the Corporations Act, a vote must not be cast (in any capacity, including as a proxy), and the Company will disregard any votes purported to be cast, on this Resolution by, or on behalf of, a member of the Key Management Personnel ("KMP"), details of whose remuneration are included in the remuneration report, or a Closely Related Party of such a member (either being a "KMP voter"), unless the KMP voter is casting a vote on behalf of a person who is not a KMP voter (including as a proxy) and either:

- a. the KMP voter is appointed as a proxy by writing that specifies the way the proxy is to vote on the Resolution; or
- b. the KMP voter is the Chair of the Meeting and the appointment of the Chair as proxy:
 - i) does not specify the way the proxy is to vote on the Resolution; and
 - ii) expressly authorises the Chair of the Meeting to exercise the proxy even if the Resolution is connected directly or indirectly with the remuneration of a KMP for the Company or the consolidated entity.

If you appoint the Chair of the Meeting as your proxy and you do not direct the Chair of the Meeting on how to vote, you will be expressly authorising the Chair of the Meeting to exercise the proxy even if the relevant Resolution is connected directly or indirectly with the remuneration of a KMP the Company or the consolidated entity.

If the Chair of the Meeting is appointed as a proxy for a person who is permitted to vote on this Resolution, the Chair of the Meeting will vote any proxies which do not indicate on their proxy form the way the Chair of the Meeting must vote in favour of this Resolution. In exceptional circumstances, the Chair of the Meeting may change their voting intention on the Resolution, in which case an ASX announcement will be made. Shareholders may also choose to direct the Chair of the Meeting to vote against the Resolution or to abstain from voting.

If you purport to cast a vote other than as permitted above, that vote will be disregarded by the Company (as indicated above) and you may be liable for breaching the voting restrictions that apply to you under the Corporations Act.

Resolutions 2 and 3

There are no voting exclusions or prohibitions on these Resolutions.

Resolutions 4 and 5

The Company will disregard any votes cast in favour of either of these Resolutions by or on behalf of:

- a. Mr Samuel Lanyon (Resolution 4) and Ms Catherine Robson (Resolution 5) and any persons(s) who will obtain a material benefit as a result of the proposed issue (except a benefit solely by reason of being a holder of ordinary securities in the Company) under the Company's Share Purchase Plan; or
- b. an associate of person referred in the preceding paragraph.

However, this does not apply to a vote cast in favour of any of these Resolutions by:

- a. a person as a proxy or attorney for a person who is entitled to vote on the Resolution(s), in accordance with directions given to the proxy or attorney to vote on the Resolution(s) in that way; or
- b. the Chair of the Meeting as proxy, or attorney, for a person who is entitled to vote on the Resolution(s) in accordance with a direction given to the Chair to vote on the Resolution(s) as the Chair decides; or
- c. a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met:
 - i) the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting, on the Resolution(s); and
 - ii) the holder votes on the Resolution(s) in accordance with directions given by the beneficiary to the holder to vote in that way.

Furthermore, a vote must not be cast as proxy on any of these Resolutions by a member of the KMP (as defined by the Corporations Act), or a Closely Related Party of a KMP and any such vote purported to be cast will be disregarded.

However, a KMP may cast a vote on any of these Resolution(s) as proxy if:

- a. the KMP is appointed as a proxy by writing that specifies the way the proxy is to vote on the Resolution(s); or
- b. the KMP is the Chair of the Meeting and the written appointment of the Chair of the Meeting as proxy:
 - i) does not specify the way the proxy is to vote on the Resolution(s); and
 - ii) expressly authorises the Chair of the Meeting to exercise the proxy even though the Resolution(s) is or are connected directly or indirectly with the remuneration of a KMP of the Company or the consolidated entity.

If you appoint the Chair of the Meeting as your proxy and you do not direct the Chair of the Meeting on how to vote, you will be expressly authorising the Chair of the Meeting to exercise the proxy even if the Resolution(s) is or are connected directly or indirectly with the remuneration of a KMP of the Company or the consolidated entity.

However, a Restricted Voter may cast a vote on any of these Resolution(s) if:

- a. it is cast by the Restricted Voter as a proxy appointed by writing that directs how to vote on the Resolution(s); and
- b. it is not cast on behalf of the Restricted Voter.

Resolution 6

The Company will disregard any votes cast in favour of this Resolution by or on behalf of:

- c. a person referred to in Listing Rule 10.14.1, 10.14.2 or 10.14.3 who is eligible to participate in the Company's Long-Term Incentive Plan, including but not limited to Mr Douglas Ward; or
- d. an associate of that person.

However, this does not apply to a vote cast in favour this Resolution by:

- d. a person as a proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with directions given to the proxy or attorney to vote on the Resolution in that way; or
- e. the Chair of the Meeting as proxy, or attorney, for a person who is entitled to vote on the Resolution in accordance with a direction given to the Chair to vote on the Resolution as the Chair decides; or
- f. a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met:
 - iii) the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting, on the Resolution; and
 - iv) the holder votes on the Resolution in accordance with directions given by the beneficiary to the holder to vote in that way.

Furthermore, a vote must not be cast as proxy on this Resolution by a member of the KMP (as defined by the Corporations Act), or a Closely Related Party of a KMP and any such vote purported to be cast will be disregarded.

However, a KMP may cast a vote on this Resolution as proxy if:

- c. the KMP is appointed as a proxy by writing that specifies the way the proxy is to vote on the Resolution; or
- d. the KMP is the Chair of the Meeting and the written appointment of the Chair of the Meeting as proxy:
 - iii) does not specify the way the proxy is to vote on the Resolution; and
 - iv) expressly authorises the Chair of the Meeting to exercise the proxy even though the Resolution is or are connected directly or indirectly with the remuneration of a KMP of the Company or the consolidated entity.

If you appoint the Chair of the Meeting as your proxy and you do not direct the Chair of the Meeting on how to vote, you will be expressly authorising the Chair of the Meeting to exercise the proxy even if the Resolution is or are connected directly or indirectly with the remuneration of a KMP of the Company or the consolidated entity.

Furthermore, in accordance with section 200E of the Corporations Act, a vote must not be cast on this Resolution (in any capacity) by or on behalf of Mr Ward or an associate thereof (any of these being a "Restricted Voter"), and any such votes attempted to be cast will be excluded.

However, a Restricted Voter may cast a vote on any of these Resolution if:

- c. it is cast by the Restricted Voter as a proxy appointed by writing that directs how to vote on the Resolution(s); and
- d. it is not cast on behalf of the Restricted Voter.

Resolutions 7 and 8

The Company will disregard any votes cast in favour of either of these Resolutions by or on behalf of:

- a. any person who participated in, or obtained a material benefit as a result of the issues (except a benefit solely by reason of being a holder of ordinary securities in the Company); or
- b. any associate of those participants.

However, this does not apply to a vote cast in favour of these Resolutions by:

- a. a person as a proxy or attorney for a person who is entitled to vote on the Resolution(s), in accordance with directions given to the proxy or attorney to vote on the Resolution(s) in that way; or
- b. the Chair of the Meeting as proxy or attorney for a person who is entitled to vote on the Resolution(s), in accordance with a direction given to the Chair to vote on the Resolution(s) as the Chair decides; or
- c. a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met:
 - i) the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting, on the Resolution(s); and
 - ii) the holder votes on the Resolution(s) in accordance with directions given by the beneficiary to the holder to vote in that way.

Resolution 9

The Company will disregard any votes cast in favour of this Resolution by any person eligible to participate in the Company's Long Term Incentive Plan, and any of their associates.

However, this does not apply to a vote cast in favour the Resolution by:

- a. a person as a proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with directions given to the proxy or attorney to vote on the resolution in that way; or
- b. the Chair of the Meeting as proxy, or attorney, for a person who is entitled to vote on the Resolution in accordance with a direction given to the Chair to vote on the Resolution as the Chair decides; or

- c. a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met:
 - i) the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting, on the Resolution; and
 - ii) the holder votes on the Resolution in accordance with directions given by the beneficiary to the holder to vote in that way.

A vote must not be cast as proxy on this Resolution by a KMP voter. However, a KMP voter may cast a vote on behalf of a person who is not a KMP voter if:

- a. the KMP voter is appointed as a proxy by writing that specifies the way the proxy is to vote on the Resolution; or
- b. the KMP voter is the Chair of the Meeting and the appointment of the Chair as proxy:
 - i) does not specify the way the proxy is to vote on the Resolution; and
 - ii) expressly authorises the Chair of the Meeting to exercise the proxy even if the Resolution is connected directly or indirectly with the remuneration of a KMP for the Company or the consolidated entity.

If you appoint the Chair of the Meeting as your proxy and you do not direct the Chair of the Meeting on how to vote, you will be expressly authorising the Chair of the Meeting to exercise the proxy even if the relevant Resolution is connected directly or indirectly with the remuneration of a KMP for the Company or the consolidated entity.

If the Chair of the Meeting is appointed as a proxy for a person who is permitted to vote on this Resolution, the Chair of the Meeting will vote any proxies which do not indicate on their proxy form the way the Chair of the Meeting must vote in favour of this Resolution. In exceptional circumstances, the Chair of the Meeting may change their voting intention on the Resolution, in which case an ASX announcement will be made. Shareholders may also choose to direct the Chair of the Meeting to vote against the Resolution or to abstain from voting.

If you purport to cast a vote other than as permitted above, that vote will be disregarded by the Company (as indicated above) and you may be liable for breaching the voting restrictions that apply to you under the Corporations Act.

Resolution 10

As at the date of despatch of this Notice, the Company is not proposing to make an issue of Equity Securities under Listing Rule 7.1A.2 and, therefore, a voting exclusion statement is not required by Listing Rule 7.3A.7.

However, if, between the date of despatch of this Notice and the date of the Meeting, the Company proposes to make an issue of Equity Securities under Listing Rule 7.1A.2, the Company will disregard votes cast in favour of this Resolution by or on behalf of:

- a. any person who is expected to participate in, or who will obtain a material benefit as a result of, the proposed issue (except a benefit solely by reason of being a holder or ordinary securities in the Company); or
- b. an associate of that person or those persons.

However, this does not apply to a vote cast in favour of the Resolution by:

- a. a person as proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with directions given to the proxy or attorney to vote on the Resolution in that way; or
- b. the Chair of the Meeting as proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with a direction given to the Chair of the Meeting to vote on the Resolution as the Chair of the Meeting decides; or
- c. a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met:
 - i) the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting; and
 - ii) the holder votes on the Resolution in accordance with directions given by the beneficiary to the holder to vote in that way.

7. Special Resolution

Resolution 10 is proposed special resolution. For a special resolution to be passed, at least 75% of votes validly cast on the Resolution by Shareholders (by number of Shares) must be in favour of this proposed Resolution.

8. Enquiries

Shareholders are invited to contact the Company Secretary at cosec@lumosdiagnostics.com or on (03) 9087 1598 if they have any queries in respect of the matters set out in these documents.

EXPLANATORY STATEMENT

ORDINARY BUSINESS

Receipt and consideration of Financial Statements and Reports

A copy of the Annual Report for the financial year ended 30 June 2026 (which incorporates the Company's Financial Report, Directors' Report (including the Remuneration Report) and the Auditor's Report) is available on the Company's website at <https://lumosdiagnostics.com/invest> or via the Company's announcement platform on ASX. Alternatively, you may obtain a copy free of charge in hard copy form by contacting the Company by email cosec@lumosdiagnostics.com or phone at (03) 9087 1598, and you may request that this occurs on a standing basis for future years. There is no requirement for Shareholders to approve the Annual Report.

Shareholders will be given reasonable opportunity at the Meeting to ask questions and make comments on the Financial Report, the Directors' Report, and the Auditor's Report. Questions for the Company's auditors relating to the conduct of the audit, preparation and contents of the audit report, accounting policies adopted by the Company in relation to the preparation of its financial statements, and the independence of the auditors in relation to the conduct of the audit, must be submitted no later than 5 business days before the Meeting to the Company Secretary at the Company's registered office or via email at cosec@lumosdiagnostics.com.

Resolution 1: Adoption of Remuneration Report

Background

Section 250R(2) of the Corporations Act requires that a resolution to adopt the Remuneration Report must be put to the vote at the annual general meeting. The vote on this Resolution is advisory only and does not bind the Directors or the Company.

The Remuneration Report is set out in the Directors' Report in the Company's Annual Report. The Remuneration Report sets out the Company's remuneration arrangements for the Directors and senior management of the Company.

In accordance with section 250SA of the Corporations Act, Shareholders will be provided with a reasonable opportunity to ask questions concerning, or make comments on, the remuneration report at the AGM.

In accordance with Division 9 of Part 2G.2 of the Corporations Act, if twenty five (25%) per cent or more of votes that are cast are voted against the adoption of the Remuneration Report at two consecutive annual general meetings, Shareholders will be required to vote at the second of those annual general meetings on a resolution (a Spill Resolution) that another meeting be held within 90 days at which all of the Company's Directors (other than the Managing Director) must be put up for re-election.

At the Company's last annual general meeting, the votes cast against the Remuneration Report were less than twenty-five (25%) per cent of the total votes cast on that resolution and, accordingly, a Spill Resolution will not, under any circumstances, be required for this Meeting.

Voting Prohibition

Refer to Note 6 for voting prohibitions.

Board Recommendation

Noting that each Director has a personal interest in their own remuneration from the Company (as such interests are described in the Remuneration Report) and, as described in the voting prohibitions on this Resolution (set out in the Notice), that each Director (or any Closely Related Party of a Director) is excluded from voting their Shares on this Resolution, the Board encourages all eligible Shareholders to cast their votes in favour of this Resolution.

Voting Intention

The Chair of the Meeting intends to vote undirected proxies in favour of this Resolution.

Resolution 2: Election of Aizaz Syed as a Director of the Company

Background

In accordance with Listing Rule 14.4 and clause 46 of the Company's Constitution, a director who is appointed to fill a casual vacancy or as an addition to the Board must not hold office without re-election past the next Annual General Meeting.

Mr Syed, having been appointed to the Board as a Non-Executive Director of the Company with effect from 12 October 2026, is retiring in accordance with these requirements and, being eligible, offers himself for election. Prior to submitting himself for election, Mr Syed has confirmed that he will have sufficient time to fulfill his duties as a Director of the Company.

Mr Syed is the Senior Portfolio and Investment Manager at Tenmile Ventures Pty Ltd based in Melbourne, where he leads, originates and manages investments as well as overseeing the overall portfolio. He has spent the last 10 years investing in early-stage technologies particularly across deep tech, healthcare, software and manufacturing as well as providing strategy, financial and commercial advice in Australia. Prior to Tenmile, he was an Investment Director at early-stage investment firm Nightingale Partners and Corporate and Investment Banking at Bank of America Merrill Lynch. Mr Syed graduated from the Australian National University with a Bachelor of Commerce and a Bachelor of Laws (Hons.). He is a Graduate of the Australian Institute of Company Directors.

The Company confirms it has conducted appropriate checks into Mr Syed's background and experience. The Board considers that Mr Syed will, if elected, qualify as a non-independent director, given his connection to Tenmile Ventures Pty Ltd, a substantial shareholder of the Company.

Voting Exclusions and Prohibitions

There are no voting exclusions or prohibitions on this Resolution.

Board Recommendation

The Board (with Mr Syed abstaining) recommends that Shareholders vote in favour of the election of Mr Syed as it considers that his qualifications, experience, skills, and expertise are appropriate for the Board position and will enable him to act in the best interests of the Company and its Shareholders.

Voting Intention

The Chair of the Meeting intends to vote undirected proxies in favour of this Resolution.

Resolution 3: Re-election of Catherine Robson as a Director of the Company

Background

Clause 47(a) of the Constitution of the Company and Listing Rule 14.4 require that a Director must retire from office no later than the longer of the third annual general meeting of the Company or three years, following that Director's last election or appointment (whichever is longer). Ms Catherine Robson, re-elected as Director on 2 November 2023, is retiring in accordance with these requirements and, being eligible, offers herself for re-election.

Ms Robson has more than 25 years of experience in management, finance and investment. Ms Robson currently serves as a Non-Executive Director for ASX listed Equity Trustees (EQT Holdings Limited) where she is the chair of the Risk Committee and chair of the superannuation subsidiary entities.

Ms Robson's other Board appointments include serving as a Non-Executive Director for Australia's largest customer owned bank, Newcastle Greater Mutual Group, where she Chairs the Audit Committee and private equity fund, the Australian Business Growth Fund, where she chairs the Audit and Risk Committee.

Ms. Robson holds a Master of Laws, majoring in Tax, from Melbourne University as well as a Bachelor of Laws and BA in Asian Studies from The Australian National University. She has a Graduate Diploma in Applied Finance and is a graduate of the Australian Institute of Company Directors Course.

Voting Exclusions and Prohibitions

There are no voting exclusions or prohibitions on this Resolution.

Board Recommendation

The Board (with Ms Robson abstaining in her capacity as Director of the Company) recommends that Shareholders vote in favour of the re-election of Ms Robson as it considers that her qualifications, experience, skills, and expertise are appropriate for the Board position and will enable her to act in the best interests of the Company and its Shareholders. The Board also considers Ms Robson as an independent Non-Executive Director of the Company.

Voting Intention

The Chair of the Meeting intends to vote undirected proxies in favour of this Resolution.

Resolutions 4 and 5: Approval to issue Free Attaching Options under Share Purchase Plan to Mr Samuel Lanyon and Ms Catherine Robson

Background

Pursuant to the Share Purchase Plan (**SPP**) announced on 27 March 2026, Directors of the Company, Mr Samuel Lanyon and Ms Catherine Robson participated in the SPP through subscribing for a maximum of \$30,000 worth of shares each at the SPP Offer price of A\$0.225 per SPP Share. Both Mr Lanyon and Ms Robson were issued with 133,333 fully paid ordinary shares each for their participation in the SPP as announced on 1 May 2026.

All eligible holders who participated in the SPP were entitled to receive one (1) Free Attaching SPP Option for every two (2) SPP Shares subscribed for and issued. As such, Resolutions 4 and 5 seek Shareholder approval to issue and allot up to a maximum of 133,333 SPP Free Attaching Options to Directors of the Company, Mr Lanyon and Ms Robson, or their nominees, as outlined below (**SPP Free Attaching Options to Participating Director**):

- Resolution 4: A maximum of 66,666 SPP Free Attaching Options to Participating Director to be issued to Mr Samuel Lanyon, Non-Executive Director and Chairman of the Company;
- Resolution 5: A maximum of 66,666 SPP Free Attaching Options to Participating Director to be issued to Ms Catherine Robson, Non-Executive Director of the Company.

The key terms of the SPP Free Attaching Options to Participating Director proposed to be issued are summarised in the table below. A copy of the full terms of the SPP Free Attaching Options are set out in Annexure A to this Notice. For clarity, the SPP Free Attaching Options to Participating Directors proposed under Resolutions 4 and 5 will be subscribed for on the same terms and conditions as those offered under the SPP to other existing eligible Shareholders.

Number and Type of Security	Key Terms
133,332 Unlisted Options	Unlisted Options, each exercisable at \$0.34 each with an expiry date of 31 December 2027

Listing Rule 10.11

ASX Listing Rule 10.11 provides that unless one of the exceptions in Listing Rule 10.12 applies, the Company, as a listed company, must not issue equity securities to persons in a position of influence without Shareholder approval.

A person in a position of influence for the purposes of Listing Rule 10.11 includes:

- a related party;
- a person who is, or was at any time in the 6 months before the issue or agreement, a substantial (30%+) holder in the Company;
- a person who is, or was at any time in the 6 months before the issue or agreement, a substantial (10%+) holder in the Company and who has nominated a director to the board of the Company pursuant to a relevant agreement which gives them a right or expectation to do so;
- an Associate of a person referred to in (a) to (c) above; and

- (e) a person whose relationship with the Company or a person referred to in (a) to (d) above is such that, in the ASX's opinion, the issue or agreement should be approved by Shareholders.

Mr Lanyon and Ms Robson are each persons in a position of influence for the purposes of Listing Rule 10.11.

The proposed issue does not fall within any of the exceptions in Listing Rule 10.12, and therefore requires the approval of the Company's Shareholders under Listing Rule 10.11.

To this end, these Resolutions seek the required Shareholder approval to issue the SPP Free Attaching Options to Participating Directors to Mr Lanyon and Ms Robson under and for the purposes of Listing Rule 10.11.

If approval is obtained under Listing Rule 10.11, in accordance with Listing Rule 7.2 (exception 14), separate approval is not required under Listing Rule 7.1.

If these Resolutions are passed, the Company will be able to proceed with that proposed issue and allotment of the SPP Free Attaching Options to Participating Directors to Mr Lanyon and Ms Robson.

If these Resolutions are not passed, Mr Lanyon and/or Ms Robson will not be able to receive their SPP Free Attaching Options to Participating Directors.

The passing of a Resolution is independent of the other Resolutions proposed and therefore approval of Resolution 4 and 5 are not interdependent on approval any other Resolution in this Notice.

Chapter 2E of the Corporations Act

Chapter 2E of the Corporations Act prohibits the Company from giving a financial benefit to a related party of the Company unless either:

- (a) the giving of the financial benefit falls within one of the exceptions to the provisions; or
- (b) Shareholder approval is obtained prior to the giving of the financial benefit.

The proposed issue of SPP Free Attaching Options to Participating Directors (which is a type of equity security, for the purposes of the Chapter 2E of the Corporations Act) constitutes the giving of a financial benefit.

A "related party" for the purposes of the Corporations Act and the Listing Rules is widely defined and includes a director of a public company, a spouse of a director of a public company or an entity controlled by a director of a public company. The definition of "related party" also includes a person whom there is reasonable grounds to believe will become a "related party" of a public company.

The Directors of the Company carefully considered the issue of these SPP Free Attaching Options to Participating Directors to Mr Lanyon and Ms Robson and formed the view that the giving of this financial benefit are on arm's length terms, as the securities proposed to be issued are on the same terms as those offered to non-related parties under the SPP Offer announced on 27 March 2026.

Accordingly, the Directors of the Company believe that the issue of these SPP Free Attaching Options to Participating Directors fall within the "arm's length terms" exception as set out in section 210 of the Corporations Act, and relies on this exception for the purposes of this Resolution. Therefore, the proposed issue of SPP Free Attaching Options to Participating Directors to the Mr Lanyon and Ms Robson requires Shareholder approval for the purposes of Listing Rule 10.11.

Information required by ASX Listing Rule 10.13

The following information in relation to the issue of the SPP Free Attaching Options to Participating Directors to Mr Lanyon and Ms Robson is provided to Shareholders for the purposes of ASX Listing Rule 10.13:

- (a) The allottees are:
 - Resolution 4 - A maximum of 66,666 SPP Free Attaching Options to Participating Directors to be issued to Mr Samuel Lanyon (or his nominee), Non-Executive Director and Chair of the Company (therefore falls under ASX Listing Rule 10.11.1); and
 - Resolution 5 - A maximum of 66,666 SPP Free Attaching Options to Participating Directors to be issued to Ms Catherine Robson (or her nominee), Non-Executive Director of the Company (therefore falls under ASX Listing Rule 10.11.1).
- (b) The maximum number of Unlisted Options to be issued is 133,332.
- (c) The full terms of the SPP Free Attaching Options to Participating Directors are set out in Annexure A to this Notice of Meeting.

- (d) The SPP Free Attaching Options to Participating Directors will be issued within 1 month of Shareholder approval being obtained by the Company.
- (e) The SPP Free Attaching Options to Participating Directors will be offered for nil cash consideration as they are free attaching Options on the basis of one attaching SPP Free Attaching Options to Participating Directors for every 2 shares issued under the SPP. Accordingly, no funds will be raised from the issue of these SPP Free Attaching Options to Participating Directors.
- (f) As provided in the Prospectus released to ASX on 10 April 2026, the funds from the SPP were intended to be applied to
 - Increasing manufacturing capacity for FebriDx by expanding operations in our existing facility in Carlsbad, California;
 - Provide funds for sales & marketing, and a medical implementation team to progress the commercial launch of FebriDx in the US;
 - Initiate feasibility of additional proprietary products for sale by Lumos;
 - Repay the amount drawn down under the loan facility; and
 - Pay for the costs of the Placement and SPP and for general working capital purposes.
- (g) The SPP Free Attaching Options to Participating Directors are not being issued under an agreement.
- (h) The issue of the SPP Free Attaching Options to Participating Directors are not intended to remunerate or incentivise the Mr Samuel Lanyon and Ms Catherine Robson. Participation in the SPP was voluntary and each of Mr Samuel Lanyon and Ms Catherine Robson paid the full subscription price for their SPP Shares. The purpose of the issue of the SPP Options to eligible Shareholders generally was to incentivise potential SPP participants to advance funds to the Company.

Voting Exclusion and Prohibition

A voting exclusion and prohibition in respect of this Note 6 has been included in this Notice of Meeting.

Board Recommendation

The Board (with Mr Lanyon and Ms Robson abstaining with respect to their respective resolution) recommends that Shareholders vote in favour of Resolutions 4 and 5.

Voting Intention

The Chair of the Meeting intends to vote undirected proxies in favour of these Resolutions.

Resolution 6: Approval to issue 17,849,593 performance rights to Mr Douglas Ward (or his nominee) as an FY27 Long Term Incentive

Background

The Company proposes, subject to Shareholder approval, to grant and issue to Mr Ward, Managing Director and Chief Executive Officer, or his nominee, under this Resolution, 17,849,593 FY27 LTI related performance rights which, if they vest, will result in the issue of up to 17,849,593 fully paid ordinary shares in the Company pursuant to the Company's Long Term Incentive Plan (LTIP).

For the avoidance of doubt, the performance rights are not a 'bonus' or 'bonus shares' – performance rights cannot be traded or sold or exchanged for any monetary value. Performance rights only vest and result in the issue of fully paid ordinary shares in the Company if, and to the extent that, the vesting conditions are satisfied and will be issued and vest in accordance with the terms and conditions of the LTIP Rules. Otherwise, the performance rights will lapse, and no Shares will be issued in relation to them.

The Company is proposing to issue 17,849,593 FY27 LTI related performance rights to Mr Ward under this Resolution to maintain his interests in the Company to approximately 5% of the total number of securities on issue in the Company, aligning his interests with that of the Shareholders of the Company.

The Board believes that it is appropriate to use performance rights to incentivise Mr Ward as this remunerates him appropriately given the circumstances of the Company. In establishing appropriate and specific vesting conditions for each tranche of the performance rights, the Board believes these rights are tailored to support the needs of the business at the time and therefore, align with Shareholder interests. The Board believes that the ownership of performance rights will be to the benefit of all Shareholders as this will motivate Mr Ward to remain in the Company's employ to carry on the role of implementing and executing the Company's strategies and overseeing operations. In particular, the Board considers that the value attributed to the performance rights (as described below) represents reasonable remuneration for Mr Ward as if the Company and Mr Ward were dealing at arm's length.

This Resolution seeks Shareholder approval to grant 17,849,593 FY27 LTI related performance rights, and to issue 17,849,593 Shares in the Company subject to satisfaction of relevant vesting conditions, to Mr Doug Ward, under the Company's LTIP and the terms described in the Explanatory Statement.

Terms of performance rights under Resolution 6

Terms	
Type	Performance Rights
Number	17,849,593
Consideration	Nil consideration
Vesting Conditions	From the Grant Date and ending as follows: 3,569,917 (20%) - Operational Vesting Conditions 3,569,919 (20%) - FebriDx Revenue > US\$7.5 million 3,569,919 (20%) - FebriDx Revenue > US\$10 million 3,569,919 (20%) - FebriDx Revenue > US\$15 million 3,569,919 (20%) - Total Revenue > US\$20 million For Vesting Condition 1 – Operational Vesting Conditions, the requirements are composed of: prior to 30 June 2027 (i) successfully establishing and operationalising manufacturing capabilities at the Company's new facility in Carlsbad, California. (ii) releasing three consecutive commercial lots, at the same scale as the currently validated manufacturing line and (iii) that meet all quality and product release specifications. Vesting of the performance rights are also subject to service condition of continued employment being satisfied at time of Vesting Date(s). The Performance Rights automatically convert to shares upon vesting.
Restrictions on Dealing	The performance rights are not transferrable. Once vesting conditions have been achieved, and the performance rights have been converted into Shares, Mr Ward will be able to deal with the Shares issued to him under this Resolution, subject to the requirements of the Company's Securities Trading Policy.
Other terms	The performance rights automatically convert into Shares upon vesting. The Performance Rights will expire if Mr Ward ceases employment or other engagement with the Company during the vesting period. The expiry date of these Performance Rights is 2 years after the date of issue.

Director's Remuneration Package and Interests

As at 28 September 2026, the details (including the amount) of the current total remuneration package of Mr Ward to whom (or to whose nominee(s)) the Shares would be issued if this Resolution is passed are:

Name of Director	Position	Remuneration Package Details
Doug Ward	Managing Director and CEO	US\$499,550 base salary per annum, annual short term incentive allocation of 50% of base salary conditional on achievement of key milestones as determined by the Board of Lumos, and long-term incentive allocation as separately approved by the Board of Lumos and Shareholders.

The above does not include the value of the proposed Performance Rights, nor the value of any securities previously issued to Mr Ward as remuneration.

The Company has prepared an assessment of the indicative fair value of the Performance Rights as summarised below. The value is indicative only, based on assumptions relevant at the date of the calculation.

The Performance Rights outlined in this Resolution have been calculated using the 10-VWAP of the Company's shares on 28 September 2026. Different assumptions may be relevant at issue date which may alter the value of the Performance Rights for financial reporting purposes.

The total remuneration package in the above table would be increased by the amount set out in the following table, based on the assumptions.

Assessment	Resolution 6
Indicative fair value per Performance Right*	
Number of Performance Rights	17,849,593
Total A\$	A\$1,999,155
AUD:USD FX Rate (as at 28 September 2026)	0.7055
Total US\$	US\$1,410,405
Value per Vesting Condition 1	US\$282,081
Value per Vesting Condition 2	US\$282,081
Value per Vesting Condition 3	US\$282,081
Value per Vesting Condition 4	US\$282,081
Value per Vesting Condition 5	US\$282,081

*The indicative fair value per Performance Rights for Resolution 6 was calculated based on the 10-day VWAP on 28 September 2026. The value per vesting condition assumes a 100% probability of achieving the condition, and as such, is the anticipated maximum value for financial reporting purposes.

As at the 28 September 2026, Mr Ward has the following direct and indirect interests in Shares, Options and/or Performance Rights of the Company:

Director/Shareholder (and/or Associate(s))	Existing		Options (Unquoted) and Performance Rights
	Shares	%	
Doug Ward	2,945,131 fully paid ordinary shares	1.16%	2,995,000 Unlisted Options exercisable at \$0.0576, expiring 26 August 2027
	8,348,083 fully paid ordinary shares		7,500,000 Unlisted Options exercisable at \$0.2987, expiring 18 July 2029
	Total: 11,293,214 fully paid ordinary shares		10,100,000 Unlisted Options exercisable at \$0.023, expiring 8 May 2028
			Performance Rights 16,000,000 Performance Rights

If Mr Ward's proposed 17,849,593 Performance Rights in this Resolution were issued and converted into shares, and there were no other issue of shares, the above percentage would increase as follows:

	Existing %	New %
17,849,593 Performance Rights converted into 17,849,593 fully paid ordinary shares	1.16%	3.00%

ASX Listing Rule requirements

As noted above, the Company is proposing to issue Performance Rights to Mr Ward (the "Issue").

Listing Rule 10.14 provides that a listed company must not permit any of the following persons to acquire equity securities under an employee incentive scheme:

- 10.14.1 a director of the company;
- 10.14.2 an associate of a director of the company; or

10.14.3 a person whose relationship with the company or a person referred to in Listing Rule 10.14.1 or 10.14.2 is such that, in ASX's opinion, the acquisition should be approved by its shareholders,

unless it obtains the approval of its shareholders.

The Issue falls within Listing Rule 10.14.1 above, as the Plan constitutes an "employee incentive scheme" under the ASX Listing Rules, and therefore requires the approval of the Company's shareholders under Listing Rule 10.14.

This Resolution therefore seeks the required shareholder approval to the Issue under and for the purposes of Listing Rule 10.14.

If Shareholders approve this Resolution, the Company will proceed with the issue of the performance rights to Mr Ward on the terms and conditions as set out in this Notice. If Shareholder approval is given for the purposes of Listing Rule 10.14, approval will not be required under Listing Rule 7.1, and the performance rights issued pursuant to this Resolution will not deplete the Company's 15% placement capacity under Listing Rule 7.1.

If Shareholders do not approve this Resolution, the proposed issue of performance rights to Mr Ward will not proceed, and the Board will need to consider alternative remuneration methods. To ensure the Company can attract and retain the executive talent, the Board considers it is important for the Company to offer incentives to its Managing Director and executives that are in line with market practice, keeping in mind that the Managing Director and CEO is based in the United States, and in alignment with the interests of Shareholders.

Furthermore, Exception 14 in Listing Rule 7.2 provides that Listing Rule 7.1 does not apply where Shareholder approval for an issue of securities is obtained under Listing Rule 10.14.

Information provided in accordance with ASX Listing Rule 10.15

- a. The proposed recipient is Mr Douglas Ward, the Managing Director and Chief Executive Officer of the Company.
- b. As a director of the Company, Mr Ward falls into the category described in Listing Rule 10.14.1.
- c. A total of 17,849,593 performance rights are being proposed to be granted to Mr Ward under this Resolution.
- d. Mr Ward's current remuneration package is comprised of US\$499,550 base salary per annum, annual short term incentive allocation of 50% of base salary conditional on achievement of key milestones as determined by the Board, and long-term incentive allocation as separately approved by the Board and Shareholders.
- e. The total number of securities previously issued to Mr Ward under the Plan are as follows, noting that they were acquired for nil consideration:
 - a. 2,995,000 Unquoted Options with each Unquoted Option exercisable at \$0.0576 and will vest on a straight-line, pro-rata basis calculated monthly over a 2 year period from 26 August 2022, expiring 26 August 2027 and will, upon exercise, entitle the holder to one fully paid ordinary share in the Company. The material terms of the LTIP are set out in Annexure C;
 - b. 7,500,000 Unquoted Options with each Unquoted Option exercisable at \$0.2987 and will vest on a straight-line, pro-rata basis calculated monthly over a 2 year period from 26 August 2022, expiring 18 July 2029 and will, upon exercise, entitle the holder to one fully paid ordinary share in the Company. The material terms of the LTIP are set out in Annexure C;
 - c. 10,100,000 Unquoted Options with each Unquoted Option exercisable at \$0.0230 and will vest over two years from 9 May 2023, with 50% of Unquoted Options vesting pro-rata calculated on a daily basis thereafter with 100% of the Unquoted Options vested by 9 May 2024. The Unquoted Options expire 8 May 2028 and will, upon exercise, entitle the holder to one fully paid ordinary share in the Company. The material terms of the LTIP are set out in Annexure C;
 - d. Up to 5,337,000 restricted Shares were approved by Shareholders at the 2024 Annual General Meeting subject to the satisfaction of the vesting condition of continued service as Managing Director for the one-year period after approval date. 3,706,331 Shares were issued on 2 June 2026 in respect of this approval.
 - e. 10,000,000 Performance Rights were approved by Shareholders at the 2025 Annual General Meeting subject to the satisfaction of the vesting conditions of continued service as Managing Director with 50% to vest after a one-year period from the grant date and the further 50% to vest after a two-year period from the grant date.

- f. 12,000,000 Performance Rights were approved by Shareholders at the 2025 Annual General Meeting subject to the satisfaction of the vesting conditions being 50% to vest at the CLIA Waiver study completion with all clinical end points met and the remaining 50% to vest following continued service as Managing Director for a two-year period from the grant date. 6,000,000 of these Performance Rights were converted to 4,166,752 Shares on 24 July 2026 following the achievement of the CLIA Waiver study completion with all clinical end points having been met.
- f. The performance rights the subject of to this Resolution will, if they vest, result in the issue of up to 17,849,593 fully paid ordinary shares in the Company pursuant to the Company's LTIP Rules. To vest, the Vesting Conditions, as outlined under *Terms of performance rights under Resolution 6*, will have to be satisfied.
- g. The Company is issuing performance rights as a form of equity security as it is a cost effective, non-cash incentive and in accordance with the information above.
- h. As set out above, the total value the entity attributes to these securities is A\$1,999,155 (US\$1,410,405 using an exchange rate of AUD:USD of 0.7055 at the time) for this Resolution.
- i. If Shareholder approval is obtained, the performance rights will be granted no later than three years after the date of the Meeting.
- j. The performance rights will be issued for nil consideration.
- k. A summary of the material terms of the LTIP Rules has been provided under **Annexure B**.
- l. No loan will be made by the Company in relation to the grant of the performance rights to Mr Ward.
- m. Details of any securities issued under the LTIP Rules will be published in each annual report of the Company relating to the period in which they were issued, along with a statement that approval for the issue was obtained under Listing Rule 10.14.
- n. Any additional persons covered by Listing Rule 10.14 who become entitled to participate in an issue of securities under the LTIP Rules after these Resolutions are approved and who are not named in this Notice and Statement will not participate until approval is obtained under that rule.

Retirement/Termination Benefits approval – section 200B and s200E Corporations Act

Sections 200B and 200E of the Corporations Act prohibit a company from giving a benefit to a person who holds (or has held in the previous three years) a managerial or executive office with the Company or its subsidiaries, if that benefit is given in connection with that person's retirement from office and is in excess of that person's average annual base salary over the relevant period, unless the benefit is approved by Shareholders or an exemption applies.

Approval is therefore sought under section 200E of the Corporations Act to allow for the Board to determine to accelerate vesting of some or all of Mr Ward's unvested Options/Performance Rights in the event Mr Ward ceases employment in 'good leaver' circumstances being cessation other than due to resignation or dismissal for cause or poor performance and for the benefit not to be a termination benefits for the purposes of the Corporations Act. Where Mr Ward ceases as a 'bad leaver' (which includes by resignation or dismissal for poor performance), all unvested Options/Performance Rights will lapse, unless the Board determines otherwise.

If Shareholder approval is obtained, the value of the approved benefits will be disregarded when calculating Mr Ward's termination benefits cap for the purpose of subsection 200F(2)(b) or subsection 200G(1)(c) of the Corporations Act. The approval will be effective from the date the Resolution is passed until the conclusion of the 2029 Annual General Meeting (that is, for a period of approximately three years).

The value of any benefit relating to the Options/Performance Rights given in connection with Mr Ward ceasing to hold managerial or executive office cannot presently be ascertained. However, matters, events and circumstances that will, or are likely to, affect the calculation of that value are:

- the number of Options/Performance Rights held by Mr Ward prior to cessation of his/her employment;
- the date when, and circumstances in which, Mr Ward ceases employment;
- whether performance hurdles are waived or (if not waived) met, and the number of Options/Performance Rights that vest (which could be all of the Options/Performance Rights held by Mr Ward; and
- the market price of the Company's shares on ASX on the date Shares are provided to Mr Ward upon vesting of the Options/Performance Rights.

Corporations Act – Chapter 2E

The Board has formed the view that the issue of performance rights to Mr Ward (or his nominee) do not require Shareholder approval under section 208 of the Corporations Act as the issues constitute “reasonable remuneration” in accordance with section 211 of the Corporations Act.

A “financial benefit” is defined in section 229 of the Corporations Act and includes granting an option to a related party. Section 228 of the Corporations Act defines a “related party” for the purposes of Chapter 2E to include:

- a. directors of the public company (section 228(2)(a)); and
- b. an entity controlled by directors of the public company (section 228(4)). Section 228(5) provides that an entity is a related party of a public company at a particular time if the entity was a related party of the public company of a kind referred to in subsection (1), (2), (3) or (4) at any time within the previous 6 months.

In reaching this view, the Board considers the proposed grant of performance rights aligns the interests of Mr Ward with the interests of Shareholders. The grant of performance rights to Mr Ward is a cost-effective form of remuneration when compared to the payment of cash consideration. The Board believes that having regard to the Company's current cash position, and the Company's objective to use available cash to fund its operations in the near future, compensating Mr Ward in performance rights is in line with current market practices.

Voting Exclusion and Prohibition

A voting exclusion and prohibition in respect of this Note 6 has been included in this Notice of Meeting.

Board Recommendation

The Board (with Mr Ward abstaining given his personal interest in this Resolution) recommends that Shareholders vote in favour of this Resolution.

Resolution 7: Ratification of the issue of 88,888,876 Placement Shares

The Company is seeking shareholder approval to ratify the prior issue of 88,888,876 Shares on 9 April 2026 at an issue price of \$0.225 per Share in accordance with the Company's Placement as announced on 27 March 2026.

The Shares were issued without shareholder approval from the Company's existing Placement Capacity under ASX Listing Rule 7.1.

ASX Listing Rules

Under ASX Listing Rule 7.4 an issue of securities will be treated as having been made with the approval of shareholders for the purposes of ASX Listing Rules 7.1 if the issue did not breach ASX Listing Rules 7.1 at the time and shareholders subsequently approve it. The Company now seeks Shareholder ratification of the issue pursuant to ASX Listing Rule 7.4 in order to retain flexibility to issue additional equity securities into the future without having to obtain shareholder approval for such issues under Listing Rule 7.1.

Broadly speaking, and subject to a number of exceptions, Listing Rule 7.1 limits the amount of equity securities that a listed company can issue without the approval of its shareholders over any 12 month period to 15% of the fully paid ordinary securities it had on issue at the start of the period.

The issue of the 88,888,876 Shares does not fit within any of these exceptions and, as it has not yet been approved by Lumos' shareholders, it effectively uses up part of the 15% limit in Listing Rule 7.1, reducing Lumos' capacity to issue further equity securities without shareholder approval under Listing Rule 7.1 for the 12 month period following the Issue Date.

Listing Rule 7.4 allows the shareholders of a listed company to approve an issue of equity securities after it has been made or agreed to be made. If they do, the issue is taken to have been approved under Listing Rule 7.1 and so does not reduce the company's capacity to issue further equity securities without shareholder approval under that rule.

If this Resolution is passed, the issue of the 88,888,876 Shares will be excluded in calculating the Company's 15% limit in Listing Rule 7.1, effectively increasing the number of equity securities it can issue without Shareholder approval over the 12 months period following the Issue Date.

If this Resolution is not passed, the issue of 88,888,876 Shares will be included in calculating the Company's 15% limit in Listing Rule 7.1, effectively decreasing the number of equity securities it can issue without Shareholder approval over the 12 months period following the Issue Date.

ASX Listing Rule 7.5 requires that the following information be provided to Shareholders for the purpose of obtaining Shareholder approval pursuant to ASX Listing Rule 7.4:

- a) the Shares were issued to institutional investors, who are clients of the Company's professional advisors and were selected by the advisors on the basis of their qualification as sophisticated and professional investors, their supportiveness of the Company's proposed use of funds information set out in the investment information as well as their general supportiveness of the Company's growth;
- b) the number and class of securities issues was 88,888,876 ordinary fully paid shares;
- c) the Shares were issued on 9 April 2026;
- d) the Shares were issued at an issue price of \$0.225 per share;
- e) the purpose of the issue was for the capital raised to be applied towards:
 - Increasing manufacturing capacity for FebriDx by expanding operations in our existing facility in Carlsbad, California;
 - Provide funds for sales & marketing, and a medical implementation team to progress the commercial launch of FebriDx in the US;
 - Initiate feasibility of additional proprietary products for sale by Lumos;
 - Repay the amount drawn down under the loan facility; and
 - Pay for the costs of the Placement and SPP and for general working capital purposes.
- f) the Shares were not issued under an agreement per Listing Rule 7.5.7.

Voting Exclusion and Prohibition

Refer to Note 6 for voting exclusions.

Board Recommendation

The Board recommends that Shareholders vote in favour of this Resolution.

Voting Intention

The Chair of the Meeting intends to vote undirected proxies in favour of these Resolutions.

Resolution 8: Ratification of the issue of Placement and Share Purchase Plan Free Attaching Options

Background

As announced to the ASX on 27 March 2026, the Company completed a Placement to raise \$20.0 million (before cost) at an issue price of \$0.225 (22.5 cents) per Placement Share to institutional, professional and sophisticated investors ("**Placement**") and a Share Purchase Plan for up to \$2.0 million to eligible shareholders in Australia and New Zealand. Participants in the Placement and Share Purchase Plan also received one (1) unlisted free attaching option for every two (2) Shares subscribed for under the equity raising.

The 44,899,966 Free Attaching Options with an exercise price of \$0.34 (34 cents) and expiring on 31 December 2027 were issued without Shareholder approval from the Company's existing Placement Capacity under ASX Listing Rule 7.1. The Company is seeking shareholder approval, pursuant to ASX Listing Rule 7.4, for the issue of 44,899,966 free attaching options with an exercise price of \$0.34 (34 cents) and expiring on 31 December 2027.

ASX Listing Rules

Listing Rules 7.1 allow the Company to issue new securities up to 15% of the existing capital of the Company in any 12-month period without the prior approval of Shareholders, unless one of the exceptions in Listing Rule 7.2 applies. The free attaching options issued on 1 May 2026 were within the Company's available placement capacity under Listing Rules 7.1.

Under Listing Rule 7.4 an issue of securities will be treated as having been made with the approval of Shareholders for the purposes of Listing Rule 7.1 if the issue did not breach Listing Rule 7.1 at the time and Shareholders subsequently approve it. As the free attaching options were within the Company's Listing Rule 7.1 placement capacity, were not issued under any of the exceptions in Listing Rule 7.2 and were not previously approved by Shareholders, the Company now seeks Shareholder ratification of the issue of the free attaching options under this Resolution pursuant to Listing Rule 7.4 in order to retain as much flexibility as possible to issue additional equity securities over the 12 month period following the issue of the Shares, without having to obtain shareholder approval for such issues under Listing Rule 7.1.

Broadly speaking, and subject to a number of exceptions, Listing Rule 7.1 limits the amount of equity securities that a listed company can issue without the approval of its shareholders over any 12 month period to 15% of the fully paid ordinary securities it had on issue at the start of the period.

The issue of the free attaching options does not fit within any of these exceptions and, as it has not yet been approved by Lumos' shareholders, it effectively uses up part of the 15% limit in Listing Rule 7.1, reducing Lumos' capacity to issue further equity securities without shareholder approval under Listing Rule 7.1 for the 12 month period following the Issue Date.

Listing Rule 7.4 allows the shareholders of a listed company to approve an issue of equity securities after it has been made or agreed to be made. If they do, the issue is taken to have been approved under Listing Rule 7.1 and so does not reduce the company's capacity to issue further equity securities without shareholder approval under that rule.

If this Resolution is approved, the prior issue of the free attaching options may be treated by the Company as having been made with Shareholder approval under Listing Rules 7.1. The Company will therefore be able to issue additional equity securities without the free attaching options subject of this Resolution counting towards the 15% threshold for the purposes of Listing Rule 7.1.

If the Resolution is not approved, the prior issue of the free attaching options will not be treated by the Company as having been made with Shareholder approval under ASX Listing Rules 7.1. The Company will therefore have the free attaching options as counting towards the 15% threshold for the purposes of ASX Listing Rule 7.1. This will limit the Company's placement capacity under the Listing Rule 7.1.

ASX Listing Rule 7.5 requires that the following information be provided to Shareholders for the purpose of obtaining Shareholder approval pursuant to ASX Listing Rule 7.4:

- a. 44,899,966 free attaching options in the Company were issued to institutional investors, who are clients of the Company's professional advisors under the Placement as detailed in Resolution 7, and to eligible shareholders from Australia and New Zealand under the Share Purchase Plan.
- b. the free attaching options were issued on 1 May 2026;
- c. the free attaching options were issued at a Nil issue price per option;
- d. A summary of the material terms of the Free Attaching Options to the Placement Shares and Share Purchase Plan have been provided under **Annexure A**.

Voting Exclusion

Refer to Note 6 for voting exclusions.

Board Recommendation

The Board recommends that Shareholders vote in favour of Resolution 8.

Voting Intention

The Chair of the Meeting intends to vote undirected proxies in favour of these Resolutions.

Resolution 9: Renewal of the Company's Long-Term Incentive Plan Rules

Background

The Company's Long Term Incentive Plan (LTIP) was initially approved by shareholders at the Company's 2021 Annual General Meeting and approved and/or renewed at the 2022, 2023, 2024 and 2025 Annual General Meetings.

This Resolution seeks Shareholders approval to 'renew' the Company's LTIP whereby the issuing capacity has reduced by incentive security issuances since the issued capacity approval at the 2025 Annual General Meeting.

The approval of the LTIP and any securities to be issued pursuant to the LTIP is sought pursuant to Listing Rule 7.2, Exception 13(b), sections 295B(2) and 260C(4) of the Corporations Act.

The Board is committed to incentivising and retaining the Company's employees (including a director employed in an executive capacity) and such other persons as the Board determine, in a manner which promotes alignment of their interests with Shareholder interests. Additionally, the Board considers equity-based compensation an integral component of the Company's remuneration platform as it allows it to be fiscally prudent by conserving cash resources while still enabling it to offer market-competitive remuneration arrangements.

No directors or their associates can or will be issued securities under the Long Term Incentive Plan (LTIP) unless Shareholder approval of specific issues to them is obtained.

The Company's LTIP was last approved by Shareholders at the Company's 2025 Annual General Meeting. The objects of the LTIP are to:

- a. provide eligible employees with an additional incentive to work to improve the performance of the Company;
- b. attract and retain eligible employees essential for the continued growth and development of the Company;
- c. promote and foster loyalty and support amongst eligible employees for the benefit of the Company; and
- d. enhance the relationship between the Company and eligible employees for the long-term mutual benefit of all parties; and
- e. provide eligible participants with the opportunity to acquire equity securities in the Company, in accordance with the LTIP.

If Shareholders approve this Resolution, the grant of Equity Securities (and the issue of any new Shares pursuant to these Equity Securities) under the LTIP will not be included in the 15% limit imposed by ASX Listing Rule 7.1 for a period of three years from the date of the AGM.

If this Resolution is not approved by Shareholders, any Equity Securities issued by the Company under the LTIP will be included in the formula to calculate the number of securities which the Company may issue in any 12-month period using ASX Listing Rule 7.1 ("15% Placement Capacity").

ASX Listing Rules

Listing Rule 7.1 requires that Shareholder approval is required for an issue of securities if the securities will, when aggregated with the securities issued by the entity during the previous 12 months, exceed 15% of the number of securities on issue at the commencement of that 12-month period.

Listing Rule 7.2 exception 13(b) provides an exception to Listing Rule 7.1 for securities issued under an employee incentive scheme, such as the EIP, within 3 years after Shareholder approval of the issue of Equity Securities under that scheme as an exception to Listing Rule 7.1. The Company therefore seeks approval of the issue of Equity Securities under the EIP pursuant to Listing Rule 7.2 Exception 13(b) to refresh its capacity under so that issues of securities under the EIP do not impede the capacity of the Company to issue up to a further 15% of its capital without Shareholder approval.

Corporations Act

Approval is also sought for the purposes of sections 259B and 260C of the Corporations Act to allow maximum flexibility and to avoid any technical Corporations Act issues.

Section 259B(1) of the Corporations Act provides that a company must not take security over Shares in itself except as permitted by the Corporations Act. Section 259B(2) of the Corporations Act provides that the Company may take security over Shares in itself under an employee share scheme that has been approved by Shareholders at a general meeting.

Under section 260C(4) of the Corporations Act, a company may financially assist a person to acquire its Shares if the financial assistance is given under an employee share scheme that is approved by Shareholders at a general meeting.

Information required for Listing Rule 7.2, exception 13(b)

Unquoted Options already issued

Since the approval of the Company's LTIP at the Annual General Meeting held in October 2025, the Company has not issued any unquoted options under the LTIP.

Performance Rights already issued

Since 24 October 2025, the date on which Shareholders approved the previous LTIP, the Company has not issued any performance rights under the LTIP.

A summary of the LTIP is set out in **Annexure B**. A copy of the LTIP is also available on the Company's website at <https://lumosdiagnostics.com/invest>.

Maximum number of Equity Securities to be issued under the LTIP

Approval is sought, for the purposes of Listing Rule 7.2, Exception 13(b), to issue up to 48,500,000 Equity Securities over a period of up to three years from the date of the Meeting. Any additional issues under the LTIP above that number would require further Shareholder approval, unless they were made from the Company's 15% placement capacity under Listing Rule 7.1.

If this Resolution is passed, the Company will be able to issue Equity Securities under the plan to eligible participants over a period of 3 years. The issue of any Equity Securities to eligible participants under the Plan (up to the maximum number of 48,500,000 Equity Securities) will be excluded from the calculation of the number of Equity Securities that the Company can issue without Shareholder approval under Listing Rule 7.1.

For the avoidance of doubt, the Company must seek Shareholder approval under Listing Rule 10.14 in respect of any future issues of securities under the Plan to a related party or a person whose relationship with the company or the related party is, in ASX's opinion, such that approval should be obtained. The future issues of securities under the Plan will still be deemed to be issued under the Plan even though Shareholder approval is obtained under the Listing Rule 10.14. Any such issues of securities to a related party under a Listing Rule 10.14 approval will not be taken into account when tracking the maximum number of equity securities to be issued under the LTIP set out in this Resolution.

If this Resolution is not passed, the Company will be able to proceed with the issue of Equity Securities under the Plan to eligible participants, but any issues of securities will reduce, to that extent, the Company's capacity to issue Equity Securities without Shareholder approval under Listing Rule 7.1 for the twelve (12) month period following the issue of the Equity Securities.

A summary of the LTIP rules is set out in the Annexure B to this Notice of Meeting.

In the Board's opinion, this Resolution will assist the Company in managing its capital requirements efficiently by ensuring that the Company's annual issue limit is not diminished by issues of securities under the LTIP, and capacity is available for capital management initiatives and acquisitions, if necessary and appropriate.

Voting Exclusion and Prohibition

Please refer to Note 6 for voting exclusions and prohibitions on this Resolution.

Board Recommendation

The Board recommends that shareholders vote in favour of renewing the approval of the Company's LTIP.

Voting Intention

The Chair of the Meeting intends to vote undirected proxies in favour of this Resolution.

SPECIAL BUSINESS

Resolution 10: Approval of 10% Placement Facility

Background

The Company is seeking Shareholder approval by way of a special resolution to have the ability, if required, to issue Equity Securities under the 10% Placement Facility. The effect of this Resolution is to allow the Directors to issue Equity Securities under Listing Rule 7.1A during the 10% Placement Period (as defined below) without, or in addition to, using the Company's 15% Capacity under Listing Rule 7.1.

ASX Listing Rules information

a. Summary of Listing Rule 7.1A

Broadly speaking, and subject to a number of exceptions, Listing Rule 7.1 limits the amount of Equity Securities that a listed company can issue without the approval of its Shareholders over any 12-month period to 15% of the fully paid ordinary securities it had on issue at the start of that period ("15% Capacity").

Under Listing Rule 7.1A, however, an eligible entity can seek approval from its members, by way of a special resolution passed at its Annual General Meeting, to increase this 15% limit by an extra 10% ("10% Placement Facility") to 25%.

An 'eligible entity' for the purposes of Listing Rule 7.1A means an entity which is not included in the S&P/ASX 300 Index, and which has a market capitalisation of \$300 million or less. The Company is, at 23 September 2026, an eligible entity for these purposes. Note however that if, on the date of the Meeting, the market capitalisation of the Company exceeds \$300 million or the Company has been included in the S&P/ASX 300 Index, then this Resolution will no longer be effective and will be withdrawn.

This Resolution seeks Shareholder approval by way of special resolution for the Company to have the additional 10% capacity provided for in Listing Rule 7.1A to issue Equity Securities without further Shareholder approval.

If this Resolution is passed, the Company will be able to issue Equity Securities up to the combined 25% limit in Listing Rules 7.1 and 7.1A without any further Shareholder approval.

If this Resolution is not passed, the Company will not be able to access the additional 10% Placement Facility to issue Equity Securities without Shareholder approval provided for in LR 7.1A and will remain subject to the 15% limit on issuing Equity Securities without Shareholder approval set out in Listing Rule 7.1.

b. Formula for calculating the 10% Placement Facility

Listing Rule 7.1A.2 provides that eligible entities which have obtained Shareholder approval at an Annual General Meeting may issue or agree to issue, during the 12-month period after the date of the Annual General Meeting, a number of Equity Securities calculated in accordance with the following formula:

$$(A \times D) - E$$

A is the number of shares on issue at the commencement of the "relevant period" (which, for the Company, is the 12-month period immediately preceding the date of the issue or agreement:

- (A) plus the number of fully paid shares issued in the relevant period under an exception in Listing Rule 7.2, other than exception 9, 16 or 17;
- (B) plus the number of fully paid shares issued in the relevant period on the conversion of convertible securities within rule 7.2 exception 9 where:
 - (i) the convertible securities were issued or agreed to be issued before the commencement of the relevant period; or
 - (ii) the issue of, or agreement to issue, the convertible securities was approved, or taken under the Listing Rules to have been approved, under rule 7.1 or rule 7.4;
- (C) plus the number of fully paid shares issued in the relevant period under an agreement to issue securities within rule 7.2 exception 16 where:
 - (i) the agreement was entered into before the commencement of the relevant period; or
 - (ii) the agreement or issue was approved, or taken under the Listing Rules to have been approved, under rule 7.1 or rule 7.4;

- (D) plus the number of fully paid shares issued in the relevant period with approval of holders of shares under Listing Rules 7.1 or 7.4;
- (E) plus the number of partly paid shares that became fully paid in the relevant period;
- (F) less the number of fully paid shares cancelled in the relevant period.

Note that A has the same meaning in Listing Rule 7.1 when calculating an entity's 15% placement capacity.

D is 10%

E is the number of Equity Securities issued or agreed to be issued under Listing Rule 7.1A.2 in the relevant period where the issue or agreement has not been subsequently approved by Shareholders under Listing Rule 7.4.

The ability of an entity to issue Equity Securities under Listing Rule 7.1A is in addition to the entity's 15% Capacity under Listing Rule 7.1. The actual number of Equity Securities that the Company will have capacity to issue under Listing Rule 7.1A will be calculated at the date of issue of the Equity Securities in accordance with the formula stated above.

c. Type and number of Equity Securities

Any Equity Securities issued under the 10% Placement Facility must be in the same class as an existing quoted class of Equity Securities of the Company. The Company, as at 23 September 2026, has on issue the following classes of quoted Equity Securities:

ASX security code and description	Total number
LDX: Ordinary Fully Paid	971,221,855

Specific information required by Listing Rule 7.3A

a. Placement Period

The period for which the approval of the 10% Placement Facility will be valid (as set out in Listing Rule 7.1A.1) commences on the date of this Meeting and expires on the first to occur of the following:

- (a) the date that is 12 months after the date of this Meeting;
 - (b) the time and date of the Company's next annual general meeting; and
 - (c) the time and date of the approval by Shareholders of a transaction under Listing Rules 11.1.2 (a significant change to the nature or scale of activities) or 11.2 (disposal of main undertaking).
- ("10% Placement Period")**

The Company will only issue and allot the Equity Securities approved under the 10% Placement Facility during the 10% Placement Period.

b. Minimum Issue Price and Cash Consideration

The Equity Securities, which are to be in an existing quoted class of the Company, will be issued for cash consideration at an issue price of not less than 75% of the VWAP for the Company's Equity Securities in the same class calculated over the 15 trading days on which trades in that class were recorded immediately before:

- (a) the date on which the price at which the Equity Securities are to be issued is agreed by the Company and the recipient of the securities; or
- (b) if the Equity Securities are not issued within 10 trading days of the date in paragraph (a) above, the date on which the Equity Securities are issued.

c. Purposes of the funds raised

The purposes for which the funds raised by an issue of Equity Securities under rule 7.1A.2 may be used by the Company include:

- (a) consideration for the acquisition(s) of the new assets and investments, including the expenses associated with such acquisition(s); and
- (b) continued expenditure on the Company's current business and/or general working capital.

d. *Risk of economic and voting dilution*

If this Resolution is approved by Shareholders and the Company issues Equity Securities under the 10% Placement Facility, the existing Shareholders' voting power in the Company will be diluted as shown in the dilution table below.

Shareholders may be exposed to economic risk and voting dilution, including the following:

- (a) the market price for the Company's Equity Securities may be significantly lower on the date of the issue of the Equity Securities than on the date of this Meeting; and
- (b) the Equity Securities may be issued at a price that is at a discount to the market price for the Company's Equity Securities on the issue date,

which may have an effect on the amount of funds raised by the issue of the Equity Securities.

The dilution table below shows the potential dilution of existing Shareholders on the basis of the market price of its quoted ordinary securities as at 23 September 2026 ("Current Share Price") and the current number of ordinary securities for variable "A" calculated in accordance with the formula in Listing Rule 7.1A.2 as at 23 September 2026.

The dilution table also shows:

- (a) two examples where variable "A" has increased by 50% and 100%. Variable "A" is based on the number of ordinary securities the Company has on issue. The number of ordinary securities on issue may increase as a result of issues of ordinary securities that do not require Shareholder approval (for example, a pro rata entitlements issue or scrip issued under a takeover offer) or future specific placements under Listing Rule 7.1 that are approved at a future Shareholders' meeting; and
- (b) two examples of where the issue price of ordinary securities has decreased by 50% and increased by 100% as against the current market price.

Variable 'A' in Listing Rule 7.1A.2		Issue Price		
		\$0.057 50% decrease in Current Share Price	\$0.115 Current Share Price	\$0.230 100% increase in Current Share Price
Current Variable A 944,820,364 Shares	10% Voting Dilution	97,122,186 Shares	97,122,186 Shares	97,122,186 Shares
	Funds raised	\$5,584,526	\$11,169,051	\$22,338,103
50% increase in current Variable A 1,417,230,546 Shares	10% Voting Dilution	145,683,278 Shares	145,683,278 Shares	145,683,278 Shares
	Funds raised	\$8,376,788	\$16,753,577	\$33,507,154
100% increase in current Variable A 1,889,640,728 Shares	10% Voting Dilution	194,244,371 Shares	194,244,371 Shares	194,244,371 Shares
	Funds raised	\$11,169,051	\$22,338,103	\$44,676,205

This dilution table has been prepared on the following assumptions:

- (a) The Company issues the maximum number of Equity Securities available under the 10% Placement Facility;
- (b) No convertible security is exercised and converted into ordinary securities before the date of the issue of the Equity Securities;
- (c) The 10% voting dilution reflects the aggregate percentage dilution against the issued share capital at the time of issue. This is why the voting dilution is shown in each example as 10%.
- (d) The table does not show an example of dilution that may be caused to a particular Shareholder by reason of placements under the 10% Placement Facility, based on that Shareholder's holding at the date of the Meeting.
- (e) The table shows only the effect of issues of Equity Securities under Listing Rule 7.1A, not under the 15% placement capacity under Listing Rule 7.1.

- (f) The issue of Equity Securities under the 10% Placement Facility consists only of ordinary securities. If the issue of Equity Securities includes quoted Options, it is assumed that those quoted Options are exercised into Shares for the purpose of calculating the voting dilution effect on existing Shareholders.
- (g) The Current Share Price is \$0.115 (11.5 cents) being the closing market price of the ordinary securities on ASX on 23 September 2026.

e. Allocation Policy

The Company's allocation policy is dependent on the prevailing market conditions at the time of any proposed issue pursuant to the 10% Placement Facility. The identity of the allottees of Equity Securities will be determined on a case-by-case basis having regard to relevant factors including, but not limited to, the following:

- (a) the methods of raising funds that are available to the Company, including but not limited to, rights issues or other issues in which existing security holders can participate;
- (b) the effect of the issue of the Equity Securities on the control of the Company;
- (c) the financial situation and solvency of the Company; and
- (d) advice from corporate, financial, and broking advisers (if applicable).

The allottees under the 10% Placement Facility have not been determined as at 23 September 2026 but may include existing substantial Shareholders, subject to compliance with Listing Rule 10.11, and/or new Shareholders who are not related parties or associates of a related party of the Company.

f. Previous Issues under Listing Rule 7.1A.2

Information about Equity Securities issued under Listing Rule 7.1A.2 in the 12-month period preceding the date of the Meeting is set out as follows:

- (a) The Company has not issued or agreed to issue any Equity Securities under Listing Rule 7.1A.2 in the 12-month period preceding the date of this Meeting.
- (b) The Company had not agreed, before the 12-month period referred to in the preceding paragraph, to issue any Equity Securities under rule 7.1A.2 where such securities remain unissued as at the date of the Meeting.

Special Resolution

The ability to issue Equity Securities under the 10% Placement Facility is subject to Shareholder approval by way of a special resolution. This means it requires approval of 75% of the votes cast by Shareholders present or represented, and eligible to vote.

Voting Exclusions

A voting exclusion statement is set out in Note 6 of the Notice.

Board Recommendation

The Board believes that this Resolution is in the best interests of the Company and unanimously recommends that Shareholders vote in favour of this Resolution.

Voting Intention

The Chair of the Meeting intends to vote undirected proxies in favour of this Resolution.

Disclosure

The Company considers this Statement to contain all material information known to it that could reasonably be required by a Shareholder in deciding how to vote on the proposed Resolutions other than information that would be unreasonable to require the Company to disclose because it has previously disclosed that information to Shareholders.

Annexure A – Placement and SPP Free Attaching Options Terms

Defined terms in this Annexure are as provided in the Prospectus released to ASX on 10 April 2026.

Terms and conditions of Placement and SPP Free Attaching Options including the SPP Free Attaching Options to Participating Directors

The SPP Free Attaching Options granted under the Offers (referred to as “**Options**”) will be issued on the following terms and conditions:

- (a) (**Entitlement**): Each Option gives the holder the right to subscribe for one Share.
- (b) (**Expiry Date**): The Options will expire at 5:00pm (AEDT) on 31 December 2027 (**Expiry Date**). An Option not exercised before the Expiry Date will automatically lapse on the Expiry Date.
- (c) (**Exercise Price**): The amount payable upon exercise of each Option is A\$0.34 per Option (**Exercise Price**).
- (d) (**Exercise Period**): The Options are exercisable at any time on or prior to the Expiry Date.
- (e) (**Quotation of the Options**): The Company will not apply for quotation of the Options on any securities exchange.
- (f) (**Transferability**): The Options are not transferable without the prior written approval of the Company at its sole discretion and subject to compliance with the Corporations Act and Listing Rules.
- (g) (**Notice of Exercise**): The Options may be exercised by notice in writing to the Company in the manner specified on the Option certificate (**Notice of Exercise**) and, if applicable, payment of the Exercise Price for each Option being exercised in Australian currency by electronic funds transfer or other means of payment acceptable to the Company.

Any Notice of Exercise of an Option received by the Company will be deemed to be a notice of the exercise of that Option as at the date of receipt of the Notice of Exercise and, if applicable, the date of receipt of the payment of the Exercise Price for each Option being exercised in cleared funds (**Exercise Date**).

- (h) (**Timing of issue of Shares on exercise**): Within 5 Business Days of receipt of the Exercise Notice accompanied by the Exercise Price, the Company will issue the number of Shares required under these terms and conditions in respect of the number of Options specified in the Exercise Notice.
- (i) (**Shares issued on exercise**): Shares issued on exercise of the Options rank equally with the then issued shares of the Company.
- (j) (**Takeovers prohibition**):
 - (i) the issue of Shares on exercise of the Options is subject to and conditional upon the issue of the relevant Shares not resulting in any person being in breach of section 606(1) of the Corporations Act; and
 - (ii) the Company will not be required to seek the approval of its members for the purposes of item 7 of section 611 of the Corporations Act to permit the issue of any Shares on exercise of the Options. 39 (k)
- (k) (**Reconstruction of capital**): If at any time the issued capital of the Company is reconstructed, all rights of an Option holder are to be changed in a manner consistent with the Corporations Act and the Listing Rules at the time of the reconstruction.
- (l) (**Participation in new issues**): There are no participation rights or entitlements inherent in the Options and holders will not be entitled to participate in new issues of capital offered to Shareholders during the currency of the Options without exercising the Options.
- (m) (**Entitlement to dividends**): The Options do not confer any entitlement to a dividend, whether fixed or at the discretion of the directors, during the currency of the Options without exercising the Options.
- (n) (**Entitlement to capital return**): The Options do not confer any right to a return of capital, whether in a winding up, upon a reduction of capital or otherwise, and similarly do not confer any right to participate in the surplus profit or assets of the Company upon a winding up, in each case, during the currency of the Options without exercising the Options.

- (o) **(Adjustments for reorganisation):** If there is any reorganisation of the issued share capital of the Company, the rights of the Option holder will be varied in accordance with the Listing Rules.
- (p) **(Adjustment for bonus issues of Shares):** If the Company makes a bonus issue of Shares or other securities to existing Shareholders (other than an issue in lieu or in satisfaction of dividends or by way of dividend reinvestment):
 - (i) the number of Shares which must be issued on the exercise of an Option will be increased by the number of Shares which the Option holder would have received if the Option holder had exercised the Option before the record date for the bonus issue; and
 - (ii) no change will be made to the Exercise Price.
- (q) **(Voting rights):** The Options do not confer any right to vote at meetings of members of the Company, except as required by law, during the currency of the Options without first exercising the Options.
- (r) **(Constitution):** Upon the issue of Shares on exercise of the Options, the holder agrees to be bound by the Company's constitution.
- (s) **(No other rights):** An Option does not give a holder any rights other than those expressly provided by these terms and those provided at law where such rights at law cannot be excluded by these terms.
- (t) **(Amendments required by ASX):** The terms of the Options may be amended as considered necessary by the Board in order to comply with the Listing Rules, or any directions of ASX regarding the terms provided that, subject to compliance with the Listing Rules, following such amendment, the economic and other rights of the holder are not diminished or terminated.

ANNEXURE B –TERMS OF THE LONG-TERM INCENTIVE PLAN (“LTIP” OR “LUMOS LTIP”)

Term	Description
Administration	The Lumos LTIP is administered by the Board.
Eligibility	Full-time and part-time employees (including a Director employed in an executive capacity) and Non-executive Directors of Lumos and any other person that the Directors determine is eligible to receive awards under the Lumos LTIP.
Awards	The Lumos LTIP provides Lumos with flexibility to grant the following types of awards: - options to subscribe for Shares, including, for participants who are subject to the U.S. Internal Revenue Code (Code), options that qualify as incentive stock options (within the meaning of Section 422 of the Code) or options that do not so qualify (each an Option); - rights to be paid a cash amount determined by the price of Shares at a specified time or the movement in price over a period of time (Incentive Rights); - ability to subscribe for Shares that may be subject to restrictions, including on transfer, until specified conditions are satisfied (Restricted Shares); or - rights to receive Shares or cash, based on specified performance factors (Performance Rights), (together Awards).
Shares	Shares issuable under the Lumos LTIP may be newly issued Shares or already issued Shares acquired and held (except in the case of participants who are citizens or residents of the United States of America or otherwise subject to the Code (U.S. Participants)) by an employee benefit trust established by Lumos. Up to 15% of the Shares on issue at the date of adoption of the Lumos LTIP may be issued pursuant to awards granted to U.S. Participants under the Lumos LTIP, all of which may be issued pursuant to incentive stock options (within the meaning of Section 422 of the Code).
Conditions	The Board will determine the terms and conditions of each award, including: - the type of Award; - the number or value of Shares or other consideration subject to the Award; - if the Award is an Option, the exercise price of the Option, or if it is any other type of Award, the purchase price (if any) payable for the Shares under the Award (except that, in the case of an Option granted to a U.S. Participant, the exercise price may never be lower than the fair market value on the date of grant); and - any vesting conditions, including service and/or performance conditions. The terms and conditions of each award will be set out in an award agreement. Options that are intended to qualify as incentive stock options (within the meaning of Section 422 of the Code) will have terms and conditions that satisfy the requirements of Section 422 of the Code.
Exercise price or Purchase price	The exercise price or purchase price will be determined by the Board (except that, in the case of an Option granted to a U.S. Participant, the exercise price may never be lower than the fair market value of a Share on the date of grant). In the case of an Option intended to qualify as an incentive stock option (within the meaning of Section 422 of the Code) granted to a U.S. Participant who owns Shares representing more than 10% of the total combined voting power of all classes of shares of Lumos or any parent or subsidiary (Ten Percent Shareholder), the exercise price must be at least 110% of the fair market value of a Share on the date of grant.
Vesting and exercise	Options will become exercisable when the applicable vesting conditions have been satisfied. The exercise of a Option may only be effected in a form and manner specified in the invitation or as otherwise determined by the Board. On exercise of an Option, and subject to a cashless exercise of Options or cash equivalent payments (see below), the participant must pay the exercise price for that Option. Incentive Rights and Performance Rights will vest and be settled by the delivery of Shares (or, where applicable, cash) when the applicable vesting or performance conditions have been satisfied. Restricted Shares will cease to be restricted when the applicable vesting conditions have been satisfied in accordance with the award agreement.

	At the time of exercise of the Options, and subject to Board approval, the participant may elect not to be required to provide payment of the exercise price for the specified number of Options, but that on exercise of those Options the Company will transfer or issue to the participant that number of Shares equal in value to the positive difference between the Market Value of the Shares at the time of exercise and the exercise price that would otherwise be payable to exercise those Options. Market Value means, at any given date, the volume weighted average price per Share traded on the ASX over the 10 trading days immediately preceding that given date, or any other calculation as determined by the Board. Unless the terms of an invitation provide otherwise, the Board may determine that the exercise of an Option or the vesting of a Performance Right will be satisfied by the Company making a cash payment to the participant in lieu of an allocation of Shares. The Board may determine that some or all of a participant's Options or Performance Rights will be settled in this manner
Maximum Number	The Company must not make an offer of Securities under the Lumos LTIP in respect of which monetary consideration is payable (either upfront, or on exercise of convertible securities) where: - the total number of Shares that may be issued or acquired upon exercise of the convertible securities offered; plus - the total number of Shares issued or that may be issued as a result of offers that were both received in this jurisdiction (as defined in section 9 of the Corporations Act) and made in connection with an employee share scheme (as defined in section 1100L(1) of the Corporations Act) at any time during the previous 3 year period, would exceed 5% of the total number of Shares on issue at the date of the offer or such other limit as may be specified by the relevant regulations or the Company's Constitution from time to time. The maximum number of Equity Securities proposed to be issued under the Lumos LTIP for the purposes of Listing Rule 7.2, Exception 13 will be as approved by Shareholders from time to time (ASX Limit). This means that, subject to the following paragraph, the Company may issue up to the ASX Limit under the Lumos LTIP without seeking Shareholder approval and without reducing its placement capacity under Listing Rule 7.1. The Company will require prior Shareholder approval for the acquisition of Equity Securities under the Lumos LTIP to Directors, their associates and any other person whose relationship with the Company or a Director or a Director's associate is such that, in ASX's opinion, the acquisition should be approved by Shareholders. The issue of Securities with Shareholder approval will not count towards the ASX Limit.
Lapsing and forfeiture	An Option will lapse on the date specified in the grant (or three years after vesting if not specified), or any earlier date specified in the award agreement (for example, upon failure to satisfy a vesting condition). However, an Option granted to a U.S. Participant who is also a California resident may not have an expiration date earlier than the 10th anniversary of the date of grant. An Option intended to qualify as an incentive stock option (within the meaning of Section 422 of the Code) may not have an expiration date later than the 10th anniversary of the date of grant, and such an Option granted to a Ten Percent Shareholder may not have an expiration date later than the 5th anniversary of the date of grant. The Company notes the provision that the expiration date be no earlier than the 10th anniversary of the date of grant for a U.S. Participant is not in keeping with the guidance in ASX Guidance Note 19 but is important for the Company's ability to attract, retain and incentivise its U.S. based Participants who make up the majority of the Company's employees. The Company notes that it is important that the Company is able to offer competitive remuneration packages relevant to the market circumstances where it operates. Restricted Shares will become subject to forfeiture or compulsory transfer, and Incentive Rights and Performance Rights will lapse, on the occurrence of a date or circumstance specified in the award agreement (for example, upon failure to satisfy a vesting or performance condition).

Dealing Restrictions	A participant may not dispose of an award in any manner, other than on his or her death or if permitted by Lumos or under an award transfer program approved by Lumos that permits transfers in specified circumstances.
Leaver	The Board may specify in the terms of an invitation or make a determination as to how an participant's Awards will be treated on the occurrence of the participant ceasing to be an eligible participant for the purposes of the Lumos LTIP. Applicable treatment may include: • vesting on the cessation date; • options only be exercisable within a specified period; or • lapse or forfeit of the Awards.
Change of control	Where there is a change of control event (for example, a takeover bid, scheme of arrangement, merger or any other transaction or event that in the Board's opinion is a change of control event), the Board may determine, subject to the ASX Listing Rules, with respect to each award, that: • Awards, to the extent not fully vested, will become vested and exercisable in full or in part; • Options may be exercised within a specific period only, otherwise they will lapse; • disposal restrictions or any other terms which apply to the Awards cease to apply; or • Lumos, on behalf of the employee, will direct the trustee to transfer trust shares into the employee's name.
Award adjustments	In order to minimise material advantage or disadvantage to a participant resulting from a variation in Lumos' issued share capital, before the delivery of Shares or payment to a participant, Lumos may, subject to the ASX Listing Rules, appropriately and proportionately adjust the exercise price and/or number and/or class of Shares subject to each outstanding Option or Award, provided that the exercise price or purchase price of any Share may not be less than the nominal value of a Share, and a fraction of a Share will not be issued. For Options granted to U.S. Participants who are residents of the State of California, a proportionate adjustment shall be made to the number of shares purchasable and the Exercise Price thereof under any Option granted pursuant to the Plan in the event of a stock split, reverse stock split, stock dividend, recapitalisation, combination, reclassification or other distribution of or on the Shares without the receipt of consideration by Lumos.
Amendments	Subject to the following paragraph, the Board may at any time by resolution amend all or any of the provisions of the Lumos LTIP, including (without limitation) the terms or conditions of any Awards granted under the Lumos LTIP and determine that any amendments to the Lumos LTIP be given retrospective effect, immediate effect or future effect. No amendment to the provisions of the Lumos LTIP may be made without consent or approval of more than 50% of the participants holding Awards where the amendment adversely affects the existing rights of the participants in respect of any granted Awards (excluding permitted amendments).
ASX Listing Rule	The Lumos LTIP and awards made under it are always subject to the ASX Listing Rules and applicable law.

GLOSSARY

The following terms have the following meanings in this Explanatory Statement:

“\$” means the Australian Dollars;

“US\$” means the United States Dollars;

“**10% Capacity** or **10% Placement Facility**” refers to the placement capacity prescribed under the Listing Rule 7.1A;

“**15% Capacity** or **15% Placement Capacity**” refers to the placement capacity prescribed under the Listing Rule 7.1;

“**10% Period** or **10% Placement Period**” means the period referred to under the Explanatory Statement for Resolution 9;

“**AEDT**” means Australian Eastern Daylight Time;

“**Annual General Meeting** or **AGM**” has the meaning given in the introductory paragraph of the Notice;

Annual Report means the Directors’ Report, the Financial Report, and Auditor’s Report, in respect to the period ended 30 June 2026;

“**Associate**” has the meaning given to that term in the Listing Rules;

“**ASX**” means ASX Limited ABN 66 630 476 970 or the Australian Securities Exchange, as the context requires;

“**ASX Limit**” means maximum number of Equity Securities proposed to be issued under the LTIP for the purposes of Listing Rule 7.2, Exception 13 as approved by Shareholders from time to time;

“**Auditor’s Report**” means the auditor’s report on the Financial Report;

“**Awards**” has the same meaning as in the Company’s LTIP;

“**Bidder**” means the person making an offer for securities under the Proportional Takeover Provisions;

“**Board**” means the Directors acting as the board of Directors of the Company or a committee appointed by such board of Directors;

“**Chair**” means the person appointed to chair the Meeting of the Company convened by the Notice;

“**CLIA**” means clinical laboratory improvement amendments;

“**Closely Related Party**” means:

- (a) a spouse or child of the member; or
- (b) has the meaning given in section 9 of the Corporations Act.

“**Code**” has the same meaning as in the Company’s LTIP;

“**Company**” means Lumos Diagnostics Holdings Limited ACN 630 476 970;

“**Constitution**” means the constitution of the Company as at the date of the Meeting;

“**Corporations Act**” means the *Corporations Act 2001* (Cth);

“**Current Share Price**” means the share price of LDX’s ordinary security as at 23 September 2026 or otherwise indicated;

“**Director**” means a Director of the Company;

“**Directors Report**” means the annual directors’ report prepared under Chapter 2M of the Corporations Act for the Company and its controlled entities;

“**Equity Security**” has the same meaning as in the Listing Rules;

“**Explanatory Statement**” means the explanatory statement which forms part of the Notice;

“**Financial Report**” means the annual financial report prepared under Chapter 2M of the Corporations Act for the Company and its controlled entities;

“**Incentive Rights**” has the same meaning as in the Company’s LTIP;

“**Key Management Personnel** or **KMP**” means persons having authority and responsibility for planning, directing and controlling the activities of the Company, directly or indirectly, including any Director (whether executive or otherwise) of the Company;

“**KMP voter**” means a KMP or a Closely Related Party of such a member;

“**LDX**” means Lumos Diagnostics Holdings Limited ACN 630 476 970;

“**Listing Rules**” means the Listing Rules of the ASX;

“**Long Term Incentive Plan** or **Plan** or **LTIP**” means the Company’s Incentive Plan as announced on to the ASX on 1 July 2021;

“**Market Value**” means has the same meaning as that given in the LTIP;

“**Meeting**” has the meaning given in the introductory paragraph of the Notice;

“**Notice**” means the Notice of Meeting accompanying this Explanatory Statement;

“**Option(s)**” has the same meaning as in the Company’s LTIP;

“**Participant**” means Eligible Participant as defined in the Company’s LTIP;

“**Performance Rights**” has the same meaning as in the Company’s LTIP;

“Placement Capacity” means the 15% or 10% capacity under Listing Rules 7.1 or 7.1A, respective, as the context requires;

“Proxy Form” means the proxy form attached to the Notice;

“Remuneration Report” means the remuneration report which forms part of the Directors’ Report of Lumos Diagnostics Holdings Limited for the financial period ended 30 June 2026 and which is set out in the 2026 Annual Report;

“Resolution” means a resolution referred to in the Notice;

“Restricted Voter” means, in respect to Resolution 2, Mr Lawrence Mehren or an associate thereof; in respect of Resolutions 3 and 5, Ms Catherine Robson or an associate thereof; and in respect of Resolution 4, Mr Samuel Lanyon for an associate thereof;

“Restricted Shares” has the same meaning as in the Company’s LTIP;

“Share” means a fully paid ordinary share in the capital of the Company;

“Shareholder” means Shareholder of the Company;

“Trading Day” means a day determined by ASX to be a trading day in accordance with the Listing Rules;

“Vesting Conditions” means any of the conditions, as outlined in the respective Resolutions outlined in the Notice, that need to be satisfied before the performance rights vest;

“Vesting Date” means any of the vesting dates referred to under the respective Resolutions outlined in the Notice, and on which the performance rights will vest subject to the achievement of the Vesting Conditions; and

“VWAP” means volume weighted average price.



Lumos Diagnostics Holdings Limited
ABN 66 630 476 970

Need assistance?



Phone:

1300 850 505 (within Australia)
+61 3 9415 4000 (outside Australia)



Online:

www.investorcentre.com/contact

LDX

MR SAM SAMPLE
FLAT 123
123 SAMPLE STREET
THE SAMPLE HILL
SAMPLE ESTATE
SAMPLEVILLE VIC 3030

Lumos Diagnostics Holdings Limited Annual General Meeting

The Lumos Diagnostics Holdings Limited Annual General Meeting will be held on Friday, 13 November 2026 at 9:00am (AEDT). You are encouraged to participate in the meeting using the following options:



MAKE YOUR VOTE COUNT

To lodge a proxy, access the Notice of Meeting and other meeting documentation visit www.investorvote.com.au and use the below information:



Control Number: 999999

SRN/HIN: I9999999999

PIN: 99999

For Intermediary Online subscribers (custodians) go to www.intermediaryonline.com

For your proxy appointment to be effective it must be received by 9:00am (AEDT) on Wednesday, 11 November 2026.



ATTENDING THE MEETING VIRTUALLY

To view the live webcast, ask questions and vote on the day of the meeting you will need to register in advance for this webinar at:

https://vistra.zoom.us/webinar/register/WN_Q_B5tsN-TH-VRNHi40k4jQ

You may elect to receive meeting-related documents, or request a particular one, in electronic or physical form and may elect not to receive annual reports. To do so, contact Computershare.



Lumos Diagnostics Holdings Limited
ABN 66 630 476 970

LDX

MR SAM SAMPLE
FLAT 123
123 SAMPLE STREET
THE SAMPLE HILL
SAMPLE ESTATE
SAMPLEVILLE VIC 3030

Need assistance?



Phone:
1300 850 505 (within Australia)
+61 3 9415 4000 (outside Australia)



Online:
www.investorcentre.com/contact



YOUR VOTE IS IMPORTANT

For your proxy appointment to be effective it must be received by **9:00am (AEDT) on Wednesday, 11 November 2026.**

Proxy Form

How to Vote on Items of Business

All your securities will be voted in accordance with your directions.

APPOINTMENT OF PROXY

Voting 100% of your holding: Direct your proxy how to vote by marking one of the boxes opposite each item of business. If you do not mark a box your proxy may vote or abstain as they choose (to the extent permitted by law). If you mark more than one box on an item your vote will be invalid on that item.

Voting a portion of your holding: Indicate a portion of your voting rights by inserting the percentage or number of securities you wish to vote in the For, Against or Abstain box or boxes. The sum of the votes cast must not exceed your voting entitlement or 100%.

Appointing a second proxy: You are entitled to appoint up to two proxies to attend the meeting and vote on a poll. If you appoint two proxies you must specify the percentage of votes or number of securities for each proxy, otherwise each proxy may exercise half of the votes. When appointing a second proxy write both names and the percentage of votes or number of securities for each in Step 1 overleaf.

A proxy need not be a securityholder of the Company.

SIGNING INSTRUCTIONS FOR POSTAL FORMS

Individual: Where the holding is in one name, the securityholder must sign.

Joint Holding: Where the holding is in more than one name, all of the securityholders should sign.

Power of Attorney: If you have not already lodged the Power of Attorney with the registry, please attach a certified photocopy of the Power of Attorney to this form when you return it.

Companies: Where the company has a Sole Director who is also the Sole Company Secretary, this form must be signed by that person. If the company (pursuant to section 204A of the Corporations Act 2001) does not have a Company Secretary, a Sole Director can also sign alone. Otherwise this form must be signed by a Director jointly with either another Director or a Company Secretary. Please sign in the appropriate place to indicate the office held. Delete titles as applicable.

PARTICIPATING IN THE MEETING

Corporate Representative

If a representative of a corporate securityholder or proxy is to participate in the meeting you will need to provide the appropriate "Appointment of Corporate Representative". A form may be obtained from Computershare or online at www.investorcentre.com/au and select "Printable Forms".

Lodge your Proxy Form:

XX

Online:

Lodge your vote online at www.investorvote.com.au using your secure access information or use your mobile device to scan the personalised QR code.

Your secure access information is



Control Number: 999999
SRN/HIN: I999999999
PIN: 99999

For Intermediary Online subscribers (custodians) go to www.intermediaryonline.com

By Mail:

Computershare Investor Services Pty Limited
GPO Box 242
Melbourne VIC 3001
Australia

By Fax:

1800 783 447 within Australia or
+61 3 9473 2555 outside Australia



PLEASE NOTE: For security reasons it is important that you keep your SRN/HIN confidential.

You may elect to receive meeting-related documents, or request a particular one, in electronic or physical form and may elect not to receive annual reports. To do so, contact Computershare.

MR SAM SAMPLE
FLAT 123
123 SAMPLE STREET
THE SAMPLE HILL
SAMPLE ESTATE
SAMPLEVILLE VIC 3030

☐ **Change of address.** If incorrect, mark this box and make the correction in the space to the left. Securityholders sponsored by a broker (reference number commences with 'X') should advise your broker of any changes.



I 9999999999

I ND

Proxy Form

Please mark ☒ to indicate your directions

Step 1 Appoint a Proxy to Vote on Your Behalf

XX

I/We being a member/s of Lumos Diagnostics Holdings Limited hereby appoint

☐ the Chairman of the Meeting **OR**

PLEASE NOTE: Leave this box blank if you have selected the Chairman of the Meeting. Do not insert your own name(s).

or failing the individual or body corporate named, or if no individual or body corporate is named, the Chairman of the Meeting, as my/our proxy to act generally at the meeting on my/our behalf and to vote in accordance with the following directions (or if no directions have been given, and to the extent permitted by law, as the proxy sees fit) at the Annual General Meeting of Lumos Diagnostics Holdings Limited to be held as a virtual meeting on Friday, 13 November 2026 at 9:00am (AEDT) and at any adjournment or postponement of that meeting.

Chairman authorised to exercise undirected proxies on remuneration related resolutions: Where I/we have appointed the Chairman of the Meeting as my/our proxy (or the Chairman becomes my/our proxy by default), I/we expressly authorise the Chairman to exercise my/our proxy on Resolutions 1, 6 and 9 (except where I/we have indicated a different voting intention in step 2) even though Resolutions 1, 6 and 9 are connected directly or indirectly with the remuneration of a member of key management personnel, which includes the Chairman.

Important Note: If the Chairman of the Meeting is (or becomes) your proxy you can direct the Chairman to vote for or against or abstain from voting on Resolutions 1, 6 and 9 by marking the appropriate box in step 2.

Step 2 Items of Business

PLEASE NOTE: If you mark the **Abstain** box for an item, you are directing your proxy not to vote on your behalf on a show of hands or a poll and your votes will not be counted in computing the required majority.

		For	Against	Abstain			For	Against	Abstain
Item 1	Adoption of Remuneration Report	☐	☐	☐	Item 7	Ratification of the issue of 88,888,876 Placement Shares	☐	☐	☐
Item 2	Election of Aizaz Syed as a Director of the Company	☐	☐	☐	Item 8	Ratification of the issue of Placement and Share Purchase Plan Free Attaching Options	☐	☐	☐
Item 3	Re-election of Catherine Robson as a Director of the Company	☐	☐	☐	Item 9	Renewal of the Company's Long-Term Incentive Plan	☐	☐	☐
Item 4	Approval to issue Free Attaching Options under Share Purchase Plan to Mr Samuel Lanyon	☐	☐	☐	Item 10	Approval of 10% Placement Facility	☐	☐	☐
Item 5	Approval to issue Free Attaching Options under Share Purchase Plan to Ms Catherine Robson	☐	☐	☐					
Item 6	Approval to issue 17,849,593 performance rights to Mr Douglas Ward (or his nominee) as a Long Term Incentive	☐	☐	☐					

The Chairman of the Meeting intends to vote undirected proxies in favour of each item of business. In exceptional circumstances, the Chairman of the Meeting may change his/her voting intention on any resolution, in which case an ASX announcement will be made.

Step 3 Signature of Securityholder(s) *This section must be completed.*

Individual or Securityholder 1	Securityholder 2	Securityholder 3	/ /
Sole Director & Sole Company Secretary	Director	Director/Company Secretary	Date
Update your communication details (Optional)			By providing your email address, you consent to receive future Notice of Meeting & Proxy communications electronically
Mobile Number	Email Address		

